

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 :  
C12P 21/06, C12N 5/00, 15/00  
C07H 15/12, 17/00, C07K 3/00  
A61K 35/14, 37/24, 37/36

A1

(11) International Publication Number:

WO 92/17602

(43) International Publication Date:

15 October 1992 (15.10.92)

(21) International Application Number: PCT/US92/02821

(22) International Filing Date: 6 April 1992 (06.04.92)

(30) Priority data:

681,702

5 April 1991 (05.04.91)

US

864,475

6 April 1992 (06.04.92)

US

(71) Applicant: THE GENERAL HOSPITAL CORPORATION OFFICE OF TECHNOLOGY AFFAIRS [US/US]; Thirteenth Street, Building 149, Suite 1101, Charlestown, MA 02129 (US).

(72) Inventors: SEGRE, Gino, V. ; 58 Sedgemoor Road, Wayland, MA 01778 (US). KRONENBERG, Henry, M. ; 48 Hastings Road, Belmont, MA 02178 (US). ABOUSAMRA, Abdul-Badi ; Four Colonial Way, Plainville, MA 02762 (US). JUPPNER, Harald ; Eight Harris Street, Boston, MA 02109 (US). POTTS, John, T., Jr. ; 129 Chestnut Street, West Newton, MA 02165 (US). SCHIPANI, Ernestina ; Four Longfellow Place, Apt. 1004, Boston, MA 02114 (US).

(74) Agent: CLARK, Paul, T.: Fish and Richardson, 225 Franklin Street, Boston, MA 02110-2804 (US).

(81) Designated States: AT (European patent), BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), MC (European patent), NL (European patent), SE (European patent).

Published

With international search report.

(54) Title: PARATHYROID HORMONE RECEPTOR AND DNA ENCODING SAME

(57) Abstract

DNA encoding a parathyroid hormone receptor; production and isolation of recombinant and synthetic parathyroid hormone receptor polypeptides and fragments; antibodies to parathyroid hormone receptors and receptor fragments; methods for screening candidate compounds for antagonistic or agonistic effects on parathyroid hormone receptor action; and diagnostic and therapeutic methods of these compounds are disclosed.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	RU	Russian Federation
CC	Congo	KP	Democratic People's Republic of Korea	SD	Sudan
CH	Switzerland	KR	Republic of Korea	SE	Sweden
CI	Côte d'Ivoire	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
DE	Germany	MC	Monaco	TG	Togo
DK	Denmark			US	United States of America

- 1 -

# PARATHYROID HORMONE RECEPTOR AND DNA ENCODING SAME

## Background of the Invention

Partial funding of the work described herein was provided by the U.S. Government, which has certain rights to the invention.

The invention relates to endocrine receptors.

A crucial step in the expression of hormonal action is the interaction of hormones with receptors on the plasma membrane surface of target cells. The formation of hormone-receptor complexes allows the transduction of extracellular signals into the cell to elicit a variety of biological responses. For example, binding of a hormone such as follicle stimulating hormone (FSH), luteinizing hormone (LH), thyroid stimulating hormone (TSH), and chorionic gonadotropin (CG), to its cell surface receptor induces a conformational change in the receptor, resulting in the association of the receptor with a transductor molecule, the stimulatory guanine nucleotide (GTP) binding protein, a component of which is ( $G_s$ ). This association stimulates adenylate cyclase activity which in turn triggers other cellular processes such as protein phosphorylation, steroid synthesis and secretion, and the modulation of ion flux. Binding of other hormones, including arginine vasopressin (VP), angiotensin II, and norepinephrine, to their cell surface receptors results in the activation of other types of GTP binding proteins components such as ( $G_p$ ), which in turn stimulates the activity of the enzyme phospholipase C. The products of phospholipase C hydrolysis initiate a complex cascade of cellular events, including the mobilization of intracellular calcium and protein phosphorylation.

Parathyroid hormone (PTH) is a major regulator of calcium homeostasis whose principal target cells occur in

- 2 -

bone and kidney. Regulation of calcium concentration is necessary for the normal function of the gastrointestinal, skeletal, neurologic, neuromuscular, and cardiovascular systems. PTH synthesis and release are controlled principally by the serum calcium level: a low level stimulates and a high level suppresses both the hormone synthesis and release. PTH, in turn, maintains the serum calcium level by directly or indirectly promoting calcium entry into the blood at three sites of calcium exchange: gut, bone and kidney. PTH contributes to net gastrointestinal absorption of calcium by favoring the renal synthesis of the active form of vitamin D. PTH promotes calcium resorption from bone by inhibiting osteoblasts and, indirectly, by stimulating differentiation of the bone-resorbing cells, osteoclasts. It also mediates at least three main effects on the kidney: stimulation of tubular calcium reabsorption, enhancement of phosphate clearance, and promotion of an increase in the enzyme that completes synthesis of the active form of vitamin D. PTH exerts these effects primarily through receptor-mediated activation of adenylate cyclase, although receptor-mediated activation of phospholipase C by PTH has also been reported (Hruska et al., J. Clin. Invest. 79:230, 1987).

Disruption of calcium homeostasis may produce many clinical disorders (e.g., severe bone disease, anemia, renal impairment, ulcers, myopathy, and neuropathy) and usually results from conditions which produce an alteration in the level of parathyroid hormone.

Hypercalcemia is a condition which is characterized by an elevation in the serum calcium level. It is often associated with primary hyperparathyroidism in which an excess of PTH production occurs as a result of a lesion (e.g., adenoma, hyperplasia or carcinoma) of the parathyroid glands. Another type of hypercalcemia,

- 3 -

humoral hypercalcemia of malignancy (HHM), is the most common paraneoplastic syndrome. It appears to result in most instances from the production by tumors (e.g., squamous, renal, ovarian or bladder carcinomas) of a novel class of protein hormone which shares amino acid homology with PTH. These PTH-related proteins (PTHrP) appear to mimic certain of the renal and skeletal actions of PTH and are believed to interact with the PTH receptor in these tissues. PTHrP is normally found at low levels in many tissues, including keratinocytes, brain, pituitary, parathyroid, adrenal cortex, medulla, fetal liver, osteoblast-like cells and lactating mammary tissues. In many HHM malignancies, PTHrP is found in the circulatory system at high levels, thereby producing the elevated calcium levels associated with HHM.

#### Summary of the Invention

The invention features isolated DNA comprising a DNA sequence encoding a cell receptor, preferably a parathyroid hormone receptor, of a vertebrate animal, which receptor has an amino acid sequence with at least 30% (preferably at least 50%, even more preferably at least 60%, and most preferably at least 75%) identity to the amino acid sequence shown in FIG. 3 (SEQ ID NO.: 3): i.e., when the closest match is made between the two amino acid sequences (using standard methods), at least 30% of the amino acid residues of the former sequence are identical to the amino acid residues of the latter sequence. By "isolated" is meant that the DNA is free of the coding sequences of those genes that, in the naturally-occurring genome of the organism (if any) from which the DNA of the invention is derived, immediately flank the gene encoding the DNA of the invention. The isolated DNA may be single-stranded or double-stranded, and may be genomic DNA, cDNA, recombinant hybrid DNA, or

- 4 -

synthetic DNA. It may be identical to a naturally-occurring, cell receptor- (e.g. PTH receptor) encoding DNA sequence, or may differ from such sequence by the deletion, addition, or substitution of one or more

5 nucleotides. Single-stranded DNAs of the invention are generally at least 8 nucleotides long, (preferably at least 18 nucleotides long, and more preferably at least 30 nucleotides long) ranging up to full length of the gene or cDNA; they preferably are detectably labelled for

10 use as hybridization probes, and may be antisense. Preferably, the isolated DNA hybridizes under conditions of high stringency to all or part of the DNA sequence show in FIG. 1 (SEQ ID NO.:1), FIG. 2 (SEQ ID NO.:2), FIG. 3 (SEQ ID NO.:3), or FIG. 6 (SEQ ID NO.:4). By

15 "high stringency" is meant, for example, conditions such as those described herein below for the isolation of human kidney PTH receptor cDNA (also see Current Protocols in Molecular Biology, John Wiley & Sons, New York, 1989, hereby incorporated by reference). Most

20 preferably, the animal is a mammal (such as an opossum, a rat, or a human), and the DNA sequence encodes substantially all of the amino acid sequence shown in FIG. 1 (SEQ ID NO.:1), FIG. 2 (SEQ ID NO.:2), FIG. 3 (SEQ ID NO.:3) or FIG. 6 (SEQ ID NO.:4); or is encoded by the

25 coding sequence of one of the plasmids deposited with the American Type Culture Collection (ATCC) and designated ATCC Accession No. 68570 or 68571. The DNA of the invention may be incorporated into a vector [which may be provided as a purified preparation (e.g., a vector

30 separated from the mixture of vectors which make up a library)] containing a DNA sequence encoding a cell receptor of the invention (e.g. parathyroid hormone receptor) or fragment of the receptor, and a cell or essentially homogenous population of cells (e.g.,

35 prokaryotic cells, or eukaryotic cells such as mammalian

- 5 -

cells) which contain the vector (or the isolated DNA described above). By "essentially homogenous" is meant that at least 99% of the cells contain the vector of the invention (or the isolated DNA, as the case may be).

5 Preferably, this vector (e.g., R15B) is capable of directing expression of a parathyroid hormone receptor (for example, in a cell transfected or transformed with the vector).

In another aspect, the invention features a cell  
10 receptor, preferably parathyroid hormone receptor, (or an essentially purified preparation thereof) produced by expression of a recombinant DNA molecule encoding the cell receptor. An "essentially purified preparation" is one which is substantially free of the proteins and  
15 lipids with which it is naturally associated.

In a related aspect, the invention features a polypeptide which includes a fragment of a naturally-occurring cell receptor of the invention. Preferably, the polypeptide includes a fragment of a naturally-  
20 occurring parathyroid hormone receptor which is capable of binding parathyroid hormone or parathyroid hormone-related protein. In preferred embodiments, this fragment is at least six amino acids long, and has a sequence selected from the group including:

- 25 (a) TNETREREVFDRLGMIYTVG; (SEQ ID NO.: 5)  
(b) YLYSGFTLDEAERLTEEEL; (SEQ ID NO.: 6)  
(c) VTFFLYFLATNYYWILVEG; (SEQ ID NO.: 7)  
(d) Y-RATLANTGCWDLSSGHKKWIIQVP; (SEQ. ID NO.: 8)  
(e) PYTEYSGTLWQIQMHYEM; (SEQ ID NO.: 9)  
30 (f) DDVFTKEEQIFLLHRAQA; (SEQ ID NO.: 10)  
(g) FFRLHCTRNY; (SEQ ID NO.: 11)  
(h) EKKYLWGFTL; (SEQ ID NO.: 12)  
(i) VLATKLRETNAGRCDTRQQYRKLK; or (SEQ ID NO. 13)  
(j) a fragment (i.e., a portion at least six  
35 residues long, but less than all) or analog of (a) - (i)

- 6 -

which is capable of binding parathyroid hormone or parathyroid hormone-related protein [wherein "analog" denotes a peptide having a sequence at least 50% (and preferably at least 70%) identical to the peptide of which it is an analog]. Preferably, the polypeptide of the invention is produced by expression of a recombinant DNA molecule or is synthetic (i.e., assembled by chemical rather than biological means). The invention provides a method for producing such a polypeptide, which method includes providing a cell containing isolated DNA encoding a cell receptor of the invention or receptor fragment and culturing this cell under conditions which permit expression of a polypeptide from the isolated DNA.

The invention also features an antibody (monoclonal or polyclonal), and a purified preparation of an antibody, which is capable of forming an immune complex with a cell receptor of the invention (preferably a parathyroid hormone receptor such as a human PTH receptor) such antibody being generated by using as antigen either (1) a polypeptide that includes a fragment of the cell receptor of the invention, or (2) a cell receptor of the invention which is on the surface of a cell. This antibody is preferably capable of neutralizing (i.e., partially or completely inhibiting) a biological activity of the cell receptor of the invention (i.e., a component of one of the cascades naturally triggered by the receptor when its ligand binds to it). In preferred embodiments, the antibody of the invention is capable of forming an immune complex with parathyroid hormone receptor and is capable of neutralizing a biological activity of the PTH receptor (i.e. adenylate cyclase activation or phospholipase C stimulation).

Also within the invention is a therapeutic composition including, in a pharmaceutically-acceptable carrier, (a) a cell receptor of the invention, (b) a

- 7 -

polypeptide containing a fragment of the cell receptor of the invention, or (c) an antibody to a cell receptor of the invention. These therapeutic compositions provide a means for treating various disorders characterized by  
5 overstimulation of the cell receptors of the invention by their ligand. In preferred embodiments, the polypeptides of the invention include the PTH receptor, fragments of the PTH receptor and antibodies which form immune  
10 antibodies are useful as diagnostics, for distinguishing those cases of hypercalcemia related to PTH or PTHrP from those which are not.

The nucleic acid probes of the invention enable one of ordinary skill in the art of genetic engineering  
15 to identify and clone cell receptor homologs or cell receptors from any species which are related to the cell receptors of the invention, expanding the usefulness of the sequences of the invention.

Other features and advantages of the invention  
20 will be apparent from the following description of the preferred embodiments and from the claims.

#### Detailed Description

The drawings will first be briefly described.

#### DRAWINGS

25 FIG. 1 is a representation of the nucleic acid and amino acid sequence encoding the opossum kidney PTH/PTHrP receptor clone, OK-H. (SEQ ID NO.: 1)

FIG. 2 is a representation of the nucleic acid and amino acid sequence encoding the opossum kidney PTH/PTHrP  
30 receptor clone, OK-O. (SEQ ID NO.: 2)

FIG. 3 is a representation of the nucleic acid and amino acid sequence encoding the rat bone PTH/PTHrP receptor clone, R15B. (SEQ ID NO.: 3)

- 8 -

FIG. 4 is a comparison of the deduced amino acid sequences encoded by cDNAs from clones OK-O and R15B.

FIG. 5 is a comparison of the deduced amino acid sequences of OK-O, OK-H and R15B, lined up according to sequence homology.

FIG. 6 is a representation of the nucleic acid and amino acid sequence encoding the human PTH/PTHrP receptor. (SEQ ID NO.: 4)

FIG. 7 is a schematic representation of the rat bone PTH/PTHrP receptor cDNA, the human genomic DNA clone HPG1 and two cDNA clones encoding the human PTH/PTHrP receptor.

FIG. 8 is a hydrophobicity plot of the deduced amino acid sequence of the human kidney PTH/PTHrP receptor. Predicted membrane-spanning domains I through VII are indicated; A, B and C indicate additional hydrophobic regions.

FIG. 9 is a graph illustrating binding of PTHrP to COS cells transfected with OK-H.

FIG. 10 is a graph illustrating stimulation of intracellular free calcium by NlePTH in COS cells transfected with OK-H.

FIG. 11 is a graph illustrating binding of PTHrP to COS cells transfected with OK-O.

FIG. 12 is a graph illustrating stimulation of intracellular free calcium by NlePTH in COS cells transfected with OK-O.

FIG. 13 is a graph illustrating binding of PTHrP to COS cells transfected with R15B.

FIG. 14 is a graph illustrating stimulation of intracellular free calcium by NlePTH in COS cells transfected with R15B.

FIG. 15 is a graph illustrating stimulation of inositol phosphate metabolism by NlePTH in COS cells transfected with OK-H, OK-O, or R15B.

- 9 -

FIG. 16 is a graph illustrating cyclic AMP accumulation in COS cells transfected with CDM-8, OK-H, R15B by NlePTH.

FIG. 17 are graphs illustrating binding of  $^{125}\text{I}$ -labelled PTH(1-34) (A and B) and  $^{125}\text{I}$ -labelled PTHrP(1-36) (C and D) to COS-7 cells transiently expressing the human kidney (A and C) and the rat bone (B and D) PTH/PTHrP receptor; competing ligands included PTH(1-34) ( $\square$ ), PTHrP(1-36) (\*), PTH(3-34) ( $\blacksquare$ ), PTH(7-34) (+). Data are given as % specific binding and represent the mean $\pm$ SD of at least three independent experiments.

FIG. 18 is a bar graph illustrating stimulated accumulation of intracellular cAMP in COS-7 cells transiently expressing the human kidney receptor. Data show the mean $\pm$ SD, and are representative of at least three independent experiments.

FIG. 19 represents a Northern blot analysis of total RNA (~ 10  $\mu\text{g}$ /lane) prepared from human kidney (A) and SaOS-2 cells (B). The blot was hybridized with the full length cDNA encoding the human kidney PTH/PTHrP receptor; positions of 28S and 18S ribosomal RNA bands are indicated.

FIG. 20 represents a Southern blot analysis of human genomic DNA digested with SstI, HindIII, and XhoI (~ 10  $\mu\text{g}$ /lane). The blot was hybridized with the full length cDNA encoding the human kidney PTH/PTHrP receptor.

FIG. 21 is a schematic diagram of the proposed arrangement, in a cellular membrane, of PTH/PTHrP rat bone receptor encoded by R15B.

#### MATERIALS AND METHODS

GENERAL: [Nle<sup>8,18</sup>, Tyr<sup>34</sup>]bPTH(1-34)amide (PTH(1-34)), [Nle<sup>8,18</sup>, Tyr<sup>34</sup>]bPTH(3-34)amide (PTH(3-34)), and [Nle<sup>8,18</sup>, Tyr<sup>34</sup>]bPTH(7-34)amide (PTH(7-34)) were obtained from Bachem Fine Chemicals, Torrance, CA; [Tyr<sup>36</sup>]PTHrP(1-

- 10 -

36)amide (PTHrP(1-36)) was synthesized as described (Keutman et al., Endocrinology 117:1230, 1985) using an Applied Biosystems Synthesizer 420A. Dulbecco's modified Eagles medium (DMEM), EDTA/trypsin, and gentamycin were from GIBCO (Grand Island, NY); fetal bovine serum (FBS) was from Hyclone Laboratory, Logan, UT. Total RNA from human kidney was provided by Per Hellman, University Hospital, Uppsala, Sweden. Oligonucleotide primers were synthesized using an Applied Biosystems 380B DNA Synthesizer. Restriction enzymes, Klenow enzyme, T4 polynucleotide Kinase and T4 DNA ligase were from New England Biolabs, Beverly, MA. Calf alkaline phosphatase was from Boehringer Mannheim, Germany. All other reagents were of highest purity available.

#### 15 CELLS

Cell lines used include COS cells, OK cells, SaOS-2 cells, CHO cells, AtT20 cells, LLC-PK1 cells, and UMR-106 cells, which are available from a variety of sources including the American Type Culture Collection (Rockland, Maryland), Accession Nos. CRL1650, CRL6551, HTB85, CCL61, CCL89, CL101, and CRL1161, respectively. ROS 17/2 and ROS 17/2.8 are available from a number of sources including Dr. Gideon Rodan (Merck Laboratories, West Point, PA). MC-3T3 cells are derived from mouse bone cells and are also available from a number of sources including Dr. Chohei Shigeno (Dept. of Biochem. Medicine, Hyoto Univ., Kyoto, Japan).

All cells were grown in a humidified 95% air, 5% CO<sub>2</sub> atmosphere and maintained in monolayer culture with Ham's F-12 or DMEM medium (Grand Island Biological Co.), supplemented with 5% or 10% fetal calf serum (M.A. Bioproducts, Walkersville, MD). The medium was changed every 3 or 4 days, and the cells were subcultured every 2 or 3 weeks by

- 11 -

trypsinization using standard methods.

#### CLONING

Isolation of cDNA clones encoding the rat and opossum PTH/PTHrP receptors: Total RNA was initially  
5 isolated from rat osteosarcoma (ROS) cells (ROS 17/2.8) and opossum kidney (OK) cells, by standard methods using guanidium isothiocyanate (Ullrich et al., Science 196: 1313, 1977; Chirgwin et al. Biochemistry 24: 5294, 1979), and centrifugation through cesium chloride (Gilsen et  
10 al., Biochemistry 13: 2633, 1974). Poly A+ RNAs (mRNAs) were then recovered after passage of the total RNAs over oligo dT columns (Pharmacia, Piscataway, NJ) by the method of Aviv and Leder (Proc. Natl. Acad Sci. USA 69: 14087, 1972). The cDNA library from the ROS 17/2.8 mRNA  
15 was prepared from poly A+ RNA using the method of Gubler and Hoffman (Gene (Amst.) 25: 263, 1983). Oligo dT-primed and random-primed cDNAs were synthesized from poly A+ ROS 17/2.8 and OK cell mRNA, respectively (Aviv and Leder, supra). The cDNAs were ligated to BstX1 linkers  
20 (Invitrogen, San Diego, CA) and size-selected by centrifugation (3 h, 55,000 xg) in a 5-20% potassium acetate gradient. The size-selected cDNA was then inserted into the plasmid vector, pCDNA I (Invitrogen), using the non-self annealing BstX1 restriction sites.  
25 The resultant plasmid libraries were then used to transform E. coli (MC1061/P3, Invitrogen) containing a larger helper plasmid, p3. The p3 plasmid possesses amber mutations in two genes which code for ampicillin and  
30 tetracycline resistance. Using ampicillin and tetracycline selection, only those cells containing both the p3 and a tRNA suppressor gene, which is contained within pCDNA I, were capable of growth. The transformed bacteria were then grown to confluence, and the plasmid  
35 DNAs isolated using standard techniques (e.g., see

- 12 -

Ausebel et al., Current Protocols in Molecular Biology, John Wiley Sons, New York, 1989). These DNAs were then taken up in a DEAE-dextran solution, and used to transfect African Green Monkey kidney (COS) cells, which  
5 had been grown to 75% confluence in "sideflasks" (Nunc, Denmark).

Screening for COS cells containing plasmids capable of expressing functionally-intact ROS or OK cell parathyroid hormone/parathyroid hormone related-protein  
10 (PTH/PTHrP) receptor proteins was performed according to Gearing et al. (EMBO J. 8: 3676, 1989), with some minor modifications including DEAE-Dextran transfection in sideflasks. Forty-eight hours after transfection, the cells were tested for binding of  $^{125}\text{I}$ -labeled [Tyr<sup>36</sup>]PTHrp  
15 (1-36) amide, using methods previously described (Yamamoto et al., Endocrinology 122: 1208, 1988), with the following exceptions: the time and temperature of the incubation were 2h and room temperature, respectively. After rinsing, the cells were fixed with 1.25%  
20 glutaraldehyde, and rinsed with 1% gelatin. After snapping off the top of the sideflask, the remaining microscope slide was dipped into NTB-2 photographic emulsion (Eastman Kodak, Rochester, NY). After 3-4 days of exposure at 4°C, the slides were developed, fixed, and  
25 stained with 0.03% toluidine blue. Screening of each slide was performed under a light microscope (Olympus). One pool of plasmid-DNA from ROS cells, and two pools of plasmid-DNA from OK cells, (10,000 independent clones), each gave rise to 3-4 transfected COS cells expressing  
30 the PTH/PTHrP receptor. These pools were subsequently subdivided. The subpools were used to transfect COS cells, and single clones were identified that expressed receptor protein capable of binding the radioligand.

Isolation of cDNA and genomic DNA clones encoding  
35 the human PTH/PTHrP receptor: A human kidney oligo dT-

- 13 -

primed cDNA library ( $1.7 \times 10^6$  independent clones) in  
lambda GT10 and a genomic library of human placental DNA  
( $2.5 \times 10^6$  independent clones) in EMBL3 (Sp6/T7) (Clontech,  
Palo Alto, CA) were screened by the plaque hybridization  
5 technique (Sambrook et al., Molecular Cloning: A  
Laboratory Manual, 2nd Ed. pp. 108-113, Cold Spring  
Harbor Laboratory, Cold Spring Harbor, NY, 1989) with the  
 $^{32}\text{P}$ -labelled (random primed labelling kit Boehringer  
Mannheim, Germany) BamHI/NotI 1.8kb restriction enzyme  
10 fragment encoding most of the coding sequence of the rat  
bone PTH/PTHrp receptor (Fig. 3). The nitrocellulose  
filters were incubated at  $42^\circ\text{C}$  for 4 hrs in a  
prehybridization solution containing 50% formamide, 4x  
saline sodium citrate (SSC;  $1 \times \text{SSC}$ : 300 mM NaCl, 30 mM  
15 NaCitrate, pH 7.0), 2x Denhardt's solution,  
10% Dextran sulphate, 100  $\mu\text{g/ml}$  salmon sperm DNA (final  
concentration). The hybridizations were carried out in  
the same solution at  $42^\circ\text{C}$  for 18-24h. Filters were  
washed with 2x SSC/0.1% SDS for 30 minutes at room  
20 temperature and then with  $1 \times \text{SSC}$ /0.1% SDS for 30 minutes  
at  $45^\circ\text{C}$ . The films were exposed at  $-80^\circ\text{C}$  for 18-24h using  
intensifying screens.

About 1,000,000 clones were screened from each  
library. Positive clones were plaque-purified and lambda  
25 phage DNA was isolated (Sambrook et al., *supra*). Cloned  
inserts were removed from phage DNA by digestion with  
restriction endonucleases HindIII and EcoRI (lambda GT10  
library), or with XhoI and SstI (EMBL3 library), and were  
then subcloned into pcDNAI (Invitrogen, San Diego, CA)  
30 using the appropriate, dephosphorylated restriction  
sites. Sequencing of the  $\text{CsCl}_2$ -purified subclones was  
performed according to Sanger et al. (Biochem 74:5463,  
1977) by the dideoxy termination method (Sequenase  
version 2 sequencing kit, United States Biochemical  
35 Corporation, Cleveland, OH).

- 14 -

Reverse transcription and polymerase chain

reaction (PCR): 3  $\mu$ g of poly (A)+ RNA from human kidney (Clontech, Palo Alto, CA) in 73.5  $\mu$ l of H<sub>2</sub>O was incubated at 100°C for 30 seconds, quenched on ice, and then added to 20  $\mu$ l of 5x RT buffer (1x RT buffer: 40 mM Tris-HCl, pH 8.2, 40 mM KCl, 6.6 mM MgCl<sub>2</sub>, 10 mM dithiothreitol, and dNTPs at 0.5 mM each), 2  $\mu$ l (4 units) RNasin (Promega Biotec, Madison, WI), 1  $\mu$ l (80 pmo/ $\mu$ l ) of the human cDNA primer H12

10 (5'-AGATGAGGCTGTGCAGGT-3'; SEQ ID NO.: 14) and 80 units of avian myeloblastosis virus reverse transcriptase (Life Sciences, St. Petersburg, FL). The reaction mixture was incubated for 40 minutes at 42°C. One-tenth of the first strand synthesis reaction mixture was then amplified by

15 PCR in a final volume of 100  $\mu$ l containing 3 mM MgSO<sub>4</sub>, 200  $\mu$ M dNTPs, 2 units of Vent polymerase (New England Biolab, Beverly, MA), and 2  $\mu$ M each of the forward and the reverse primers (PCR conditions: denaturing for 1 min at 94°C, annealing for 1 min at 50°C, and extension at

20 72°C for 3 minutes; 40 cycles).

Two independent PCRs were performed using two different forward primers: i) degenerate primer RK-1 (5'-GGAATTCCATGGGAGCGGCCCGGAT-3'; SEQ ID NO.: 15) based on

25 the 5' coding end of the two previously cloned PTH/PTHrP receptors (described above), and ii) primer RK-2 (5'-CGGGATCCCGCGGCCCTAGGCGGT-3'; SEQ ID NO.: 16) based on the 5' untranslated region of the human genomic clone

30 HPG1. Both PCR reactions used the reverse primer H26 (5'AGTATAGCGTCCTTGACGA-3'; SEQ ID NO.: 17) representing nucleotides 713 to 731 of the coding region of the human PTH/PTHrP receptor (Fig. 4). PCR products were blunt-ended using Klenow enzyme and cloned into

35 dephosphorylated pcDNAI cut with EcoRV.

- 15 -

Northern blot analysis: Total RNA was extracted from SaOS-2 cells and from human kidney by the guanidine thiocyanate method (Chirgwin et al., Biochem. 18:5294, 1979). For Northern blot analysis, ~10 µg of total RNA was subjected to electrophoresis on a 1.5%/37% formaldehyde gel and blotted onto nitrocellulose filters (Schleicher and Schuell, Keene, NH). The hybridization conditions were the same as those for screening the phage libraries (see above). The filters were washed at a final stringency of 0.5x SSC/0.1% SDS for 30 min at 60°C and exposed for autoradiography.

Southern blot analysis: Human genomic DNA was prepared using the SDS/proteinase K method (Gross-Bellard et al., Eur. J. Biochem. 36:32, 1973). For Southern analysis, ~10 µg of DNA was digested with SstI, PvuII and XhoI; subjected to electrophoresis on a 0.8% agarose gel; and blotted onto nitrocellulose membranes (Schleicher and Schuell, Keene, NH). The hybridization conditions were the same as those for screening the phage libraries (see above). The filters were washed at a final stringency of 0.5x SSC/0.1% SDS for 30 min at 55°C and exposed for autoradiography.

#### FUNCTIONAL ASSAYS

Tests to characterize the functional properties of the cloned receptors expressed on COS cells included:

- I) binding of PTH and PTHrP fragments and analogues,
- II) stimulation of cyclic AMP accumulation by PTH and PTHrP fragments and analogues,
- III) increase of intracellular free calcium by PTH and PTHrP fragments and analogues, and
- IV) activation of inositol phosphate metabolism by PTH and PTHrP fragments and analogues. The methodologies are as follows:

- 16 -

Radioreceptor Assay

[Nle<sup>8</sup>,Nle<sup>18</sup>,Tyr<sup>34</sup>]bPTH-(1-34)amide (NlePTH), and [Tyr<sup>36</sup>]PTHrP(1-36)amide(PTHrP) were iodinated with Na<sup>125</sup>I (carrier free, New England Nuclear, Boston, MA) as previously reported (Segre et al., J. Biol. Chem. 254: 6980, 1979), and purified by reverse-phase HPLC. In brief, the labeled peptide was dissolved in 0.1% trifluoroacetic acid (TFA), applied to a C<sub>18</sub> Sep-pak cartridge (Waters Associates, Inc., Milford, MA) and eluted with a solution of 60% acetonitrile in 0.1% TFA. After lyophilization, the radioligand then was applied to C<sub>18</sub>-μBondapak column (3.9 mm x 30 cm. Waters Associates) and eluted over 30 min with a linear gradient of 30-50% acetonitrile-0.1% TFA at a flow rate of 2 ml/min. The radioligand eluted in two peaks; the first peak, which eluted at approximately 38% acetonitrile, was used in these studies because it gave higher total and specific bindings. The specific activity was 500 ± 75 mCi/mg, which corresponds to an average iodine-peptide ratio of 1.

COS-7 cells were grown in 15 cm plates in DMEM, 10% heat-inactivated FBS, 10 mg/L gentamycin until 80-90% confluent. Twenty-four hours after transfection by the DEAE/Dextran method (Sambrook et al., *supra*), with 1-2 μg of plasmid DNA, the cells were trypsinized and replated in multiwell plastic dishes (16 or 35 mm diameter, Costar, Cambridge, MA) at a cell concentration of 5 x 10<sup>4</sup> cells/cm<sup>2</sup>). Cell number increased only slightly after transfection. After continuing culture for another 48 h, radioreceptor assays were performed. The culture medium was replaced with buffer containing 50 mM Tris-HCL (pH 7.7), 100 mM NaCl, 2 mM CaCl<sub>2</sub>, 5 mM KCL, 0.5% heat-inactivated fetal bovine serum (GIBCO), and 5% heat-inactivated horse

- 17 -

serum (KC Biological Inc., Lenexa, KS) immediately before studies were initiated. Unless otherwise indicated, studies were conducted with cells incubated in this buffer at 15°C for 4 h with  $4 \times 10^5$  cpm/ml ( $9.6 \times 10^{-11}$  M) of  $^{125}\text{I}$ -labeled NlePTH or PTHrP.

Incubations were terminated by aspirating the buffer, and repeatedly (x3) washing the culture dishes containing the adherent cells with chilled 0.9% NaCl solution, over a 15 sec period. Cell-bound radioactivity was recovered by the sequential addition (x3) of 1 N NaOH (200  $\mu\text{l}$ ) to each well. After 30 min at room temperature, the NaOH was transferred to a glass tube. A second and third extraction with 1 N NaOH (200  $\mu\text{l}$ ) were combined with the first, and the total radioactivity was counted in a  $\gamma$ -spectrometer (Packard Instruments, Downers Grove, IL). Tracer adherence to culture vessel without cells was negligible (<0.2% of total counts added), if vessels were preincubated with culture medium.

#### Determinations of cAMP accumulation

Intracellular cAMP accumulation was measured as described previously (Abou-Samra et al., J. Biol. Chem. 262:1129, 1986). Cells in 24-well plates were rinsed with culture medium containing 0.1% BSA and 2mM IBMX. The cells were then incubated with PTH or PTHrP for 15 min. at 37° C. The supernatant was removed and the cells immediately frozen by placing the whole plate in dry ice powder. Intracellular cAMP was extracted by thawing the cells in 1ml of 50 mM HCl and analyzed by a specific radioimmunoassay using an anti-cAMP antibody (e.g., Sigma, St. Louis, MO). A cAMP analog (2'-O-monosuccinyl-adenosine 3':5'-cyclic monophosphate tyrosyl methyl ester, obtained from Sigma) which was used a tracer for cAMP was iodinated by the chloramine T method. Free iodine was removed by adsorbing the iodinated cAMP analog onto a C18 Sep-pak cartridge (Waters, Milford, MA).

- 18 -

After washing with  $\text{dH}_2\text{O}$ , the iodinated cAMP analog was eluted from the Sep-pak Cartridge with 40% acetonitrille (ACN) and 0.1% trifluoroacetic acid (TFA). The iodinated cAMP analog was lyophilized, reconstituted in 1 ml 0.1% TFA, and injected into a C18 reverse phase HPLC column (Waters). The column was equilibrated with 10% ACN in 0.1% TFA, and eluted with gradient of 10-30% ACN in 0.1% TFA. This allows separation of the mono-iodinated cAMP analog from the non-iodinated cAMP analog. The tracer is stable for up to 4 months when stored at  $-20^\circ\text{C}$ . The standard used for the assay, adenosine 3':5'-cyclic monophosphate, was purchased from Sigma. Samples (1-10  $\mu\text{l}$  of HCl extracts) or standards (0.04-100 fmol/tube) were diluted in 50 mM Na-acetate (pH 5.5), and acetylated with 10  $\mu\text{l}$  of mixture of triethylamine and acetic anhydride (2:1 vol:vol). After acetylation, cAMP antiserum (100  $\mu\text{l}$ ) was added from a stock solution (1:4000) made in PBS (pH 7.4), 5 mM EDTA and 1% normal rabbit serum. The tracer was diluted in PBS (pH 7.4) with 0.1% BSA, and added (20,000 cpm/tube). The assay was incubated at  $4^\circ\text{C}$  overnight. The bound tracer was precipitated by adding 100  $\mu\text{l}$  of goat anti-rabbit antiserum (1:20 in PBS) and 1 ml of 7% polyethyleneglycol (MW 5000-6000), centrifuging at 2000 rpm for 30 min. at  $4^\circ\text{C}$ . The supernatant was removed and the bound radioactivity was counted in a  $\gamma$ -counter (Micromedic). Standard curves were calculated using the four-parameter RIA program supplied by Micromedic. Typically, the assay sensitivity is 0.1 fmol/ tube, and the standard concentration that displaces 50% of tracer is 5 fmol/tube.

In an alternative method for assaying cAMP accumulation, COS cells transfected with PTH/PTHrP receptor cDNA are harvested with a plastic policeman into a solution containing 10 mM Tris-HCl (pH 7.5), 0.2 mM

- 19 -

MgCl<sub>2</sub>, 0.5 mM ethyleneglycolbis( $\beta$ -amino ethyl ether) *N,N'*-tetra-acetic acid (EGTA) (Sigma) and 1 mM dithiothreitol (Sigma). Cells are homogenated by 20 strokes of tightly-fitting Dounce homogenizer, and centrifuged at 13,000 x g for 15 min at 4°C (Eppendorf, type 5412, Brinkmann Instruments, Inc., Westburg, NY). The pellet containing the plasma membranes is resuspended in the same buffer by several strokes with a Dounce homogenizer, and further diluted with the same buffer to a protein concentration of approximately 1.2 mg/ml, as determined by the method of Lowry et al. (Lowry et al., J. Biol. Chem 193: 265, 1951). Approximately 30  $\mu$ g (25  $\mu$ l) membrane are incubated with varying concentrations of hormone or vehicle alone for 10 min at 37°C (final volume, 100  $\mu$ l) in 50 mM Tris-HCl (pH 7.5), 0.8 mM ATP, 4 x 10<sup>6</sup> cpm [ $\alpha$ -<sup>32</sup>P] ATP (New England Nuclear, Boston, MA), 9 mM theophylline, 4.2 mM MgCl<sub>2</sub>, 26 mM KCl, 0.1% BSA, and an ATP-regenerating system containing 5 mM creatine phosphate (Schwartz/Mann Division, Becton-Dickenson & Co., Orangeburg, NY) and 0.1 mg/ml creatine phosphokinase (Shwartz/Mann). Incubations are initiated by addition of the membrane suspension and terminated by addition of 100  $\mu$ l of a solution containing 20 mM cAMP, approximately 50,000 cpm [<sup>3</sup>H]cAMP, and 80 mM ATP. The reaction mixture is boiled, and the [<sup>32</sup>P]cAMP generated is purified by sequential chromatography on ion-exchange columns (Dowex 50 W-X4, Biorad Lab, Richmond, CA) and alumina (Sigma). The [<sup>32</sup>P]cAMP may be counted in a  $\beta$ -scintillation counter (Packard Instrument Co.), with correction for recovery of [<sup>3</sup>H]cAMP.

#### Determination of intracellular free calcium

Measurements of intracellular calcium levels in cells transfected with PTH/PTHrP receptor cDNAs were performed using Fura-2 AM (acetomethoxy ester of Fura-2,

- 20 -

Molecular Probes Inc., Eugene, OR) loaded cells. Details of the methodology are:

Coverslips plated with COS cells were incubated in Fura-2 AM loading buffer containing, in mM: HEPES (N-[2-Hydroxyethyl]piperazine-N'-[2-ethanesulfonic acid]), 20;  $\text{CaCl}_2$ , 1; KCl 5; NaCl, 145;  $\text{MgSO}_4$ , 0.5;  $\text{NaHCO}_3$ , 25;  $\text{K}_2\text{HPO}_4$ , 1.4; glucose, 10; and Fura-2 AM 91-(2'-5'-carboxyoxazol-2'-yl)-6-aminobenzofuran-5oxy-(2'-amino-5'-methylphenoxy)ethane-N,N,N',N'-tetraacetic acid acetomethoxy ester), 0.5; at 37°C at pH7.4, aerated with 95% air and 5%  $\text{CO}_2$  for 45 minutes. Cells loaded with Fura-2 AM were then washed with a modified Krebs-Heinseleit (KH) buffer containing, in mM: HEPES, 20;  $\text{CaCl}_2$ , 1; KCl, 5; NaCl, 145;  $\text{MgSO}_4$ , 0.5;  $\text{Na}_2\text{HPO}_4$ , 1; glucose, 5; pH7.4. To check that cleavage of the ester occurred, the excitation spectra after different times of Fura-2 AM incubation were measured. At 5 min. after the start of incubation, the excitation spectrum peaked at approximately 360 nm, reflecting incomplete hydrolysis of Fura-2 AM, whereas beyond 30 min. the excitation spectrum peaked at 345 nm, characteristic of Fura-2.

To measure fluorescence of individual cells, the cover slips were placed in a microscope tissue chamber (Biophysica Technologies, Inc., MD). The chamber consisted of a shallow, sloped compartment made of Teflon with a silicone rubber seal. The cover slips served as the bottom of the chamber. A heater/cooler ring was encased in the silicone rubber which sealed the coverslip in place. Temperatures were varied between 22°C and 37°C by applying 0-7.4 V to the heater. If the temperature is not specifically stated, the experiment was performed at 37°C. The chamber was mounted on the stage of an inverted microscope (Zeiss IM-35, Thornwood, NY). Fura-2 fluorescence was excited with a 75 watt Xenon arc lamp placed at the focal point of a condenser (Photon

- 21 -

Technologies International (PTI) Inc., NJ). Grating monochromators, alternated by a rotating chopper in which mirror vanes alternate with transmitting sectors, were used for selecting wavelengths. The monochromator outputs were combined to form a common optical path which exited the source housing through an adjustable iris. The light then passed through quartz lenses and a dichroic mirror through a 100x Nikon Fluor objective. A photon-counting PMT device detection was used to measure the light output. Data analysis was performed using PTI software run on an IBM-compatible AT/286 computer using the MS-DOS operating system. Data was retained and manipulated in a packed binary format.

Intracellular calcium concentrations were calculated according to the formula:  $[Ca^{2+}]_i = K_d(R - R_{min}) / (R_{max} - R)B$ , where R is the ratio of fluorescence of the cell at 340 and 380 nm;  $R_{max}$  and  $R_{min}$  represent the ratios of Fura-2 fluorescence intensity at 340 and 380 nm excitation wavelengths in the presence of a saturating amount of calcium and effectively zero calcium, respectively; B is the ratio of fluorescence of Fura-2 at 380 nm in zero calcium to that in saturating amounts of calcium; and  $K_d$  is the dissociation constant of Fura-2 for calcium. To determine  $R_{max}$ , at the end of an experiment ionomycin was added to the Fura-2 AM loaded cells to equilibrate  $Ca^{2+}$  between the extracellular (1mM) and intracellular environments. To calculate  $R_{min}$ , 1mM EGTA was then added to the bathing solution. Different dissociation constants were used at the different temperatures: 224 nM at 34-37°C and 135 nM at 24-27°C.

#### Determination of inositol phosphate

The level of inositol phosphate metabolism was determined in COS cells transfected with PTH/PTHrP

- 22 -

receptors using previously published methods (Bonventre, et al., J. Biol. Chem. 265: 4934, 1990).

## RESULTS

### Molecular characterization

5 Two independent clones (OK-H and OK-O), both of which were isolated from the OK cell cDNA library, had lengths of approximately 2 kilobases. The determined nucleotide sequence and predicted amino acid sequence of these clones are shown in Figs. 1 (SEQ ID NO.:1) and 2  
10 (SEQ ID NO.:2) respectively. The R15B clone isolated from the ROS cell cDNA library had a length of approximately 4 kilobases. The determined nucleotide sequence and predicted amino acid sequence of the rat bone PTH/PTHrP receptor is depicted in Fig. 3 (SEQ ID  
15 NO.:3).

The three cDNA clones appear to be full-length by the criteria of having codons encoding methionine residues that are predicted to be the likely candidates as initiator methionines. These methionine codons are  
20 followed by amino acid sequences (deduced from the DNA) with properties suggesting that they are "signal-peptide" sequences. All three receptor cDNAs have stop codons at locations that permit these receptors to "fit" a putative seven-membrane spanning model, a model typical for G-  
25 protein-linked receptors. Most importantly, all three cloned receptors bind ligands and, when activated, are capable of activating intracellular effectors. These properties suggest that all three of the isolated clones encode full-length cDNAs.

30 Fig. 4 demonstrates the high degree of homology between the amino acid sequences encoded by the cDNAs from OK-O and ROS 15B. There is an overall 87% homology and a 77.8% amino acid identity between these two receptors. This high level of identity over long

- 23 -

stretches of amino acids demonstrates that the amino acid sequence of the PTH receptor is evolutionarily conserved to a high degree. This allows the data from both OK-O and R15B to be extrapolated to other species, including human.

Fig. 5 shows the deduced amino acid sequences of all three cloned cDNAs lined up according to sequence homology. The OK-H sequence is identical to OK-O except in the C-terminus tail, where the OK-O sequence totals 585 amino acids whereas the OK-H sequence stops at 515 amino acids. This difference is attributable to a single nucleotide (G) deleted in the OK-H sequence compared to the OK-O sequence, causing a frame shift and early stop codon in the former. It is not known whether OK-O and OK-H represent the products of two separate genes or of a laboratory artifact.

Some G-protein-coupled receptors are encoded by intronless genes (Kobilka et al., *Nature* 329:75, 1987); Kobilka et al., *J. Biol. Chem.* 262:7321, 1987; Heckert et al., *Mol. Endocrinol.* 6:70, 1992; Kobilka et al., *Science* 238:650, 1987; Bonner et al., *Science* 237:527, 1987; Sunahara et al., *Nature* 347:80, 1990). To isolate a human PTH/PTHrP receptor cDNA, both a human cDNA library and a human genomic library were screened with a probe (BamHI/NotI) representing most of the coding region of the rat bone PTH/PTHrP receptor (Fig. 3). Screening the human kidney cDNA library led to the isolation of the clone HK-1 (Fig. 6) [SEQ ID NO.: 6]. Since one of the two EcoRI cloning sites of lambda GT10 proved to be eliminated as a result of the library construction, the HindIII/EcoRI phage fragment containing the cDNA insert and ~250 bp of the 37 kb (left) lambda arm was subcloned into the corresponding restriction sites in pCDNAI. DNA sequencing revealed that the cloned cDNA contained ~1000 bp of the 3' coding region and ~200 bp of the 3' non-

- 24 -

coding region including an A-rich 3' end. The coding region 5' to the XhoI site was subsequently used to rescreen the library and led to the isolation of the clone HK-2 which, after subcloning into pCDNAI, proved to contain ~1400 bp of the coding region. For the third screening of the library, the PvuII/PstI fragment of HK-2 was used; the isolated clone HK-3 proved to be identical to HK-2.

The genomic library screening ( $\sim 10^6$  pfu) resulted in the isolation of four independent clones. Comparison of Southern blot analyses of restriction enzyme digests of these clones with that of normal genomic DNA, revealed that one 15 kb genomic clone, HPG1 (also referred to as HG4A), contained a SstI/SstI fragment that had the same size as one hybridizing DNA species from normal human genomic DNA digested with SstI (see below). The hybridizing 2.3 kb SstI/SstI DNA fragment and an ~8 kb XhoI fragment which comprised the SstI/SstI fragment were both subcloned into pCDNAI. Further Southern blot analysis of the SstI/SstI DNA fragment revealed that an ~1000 bp BamHI/SstI fragment encoded a portion of the human PTH/PTHrP receptor which later proved to represent the exon encoding the putative signal peptide and the 5' non-translated region which is interrupted by an ~1000 bp intron (Fig. 7).

To isolate the remaining ~450 nucleotides of the coding region, poly (A)+ RNA from human kidney was reverse transcribed after priming with H12 (Fig. 7). After single strand synthesis, two independent PCRs were performed using two different forward primers: i) a degenerate primer RK-1 based on the 5' coding end of the two previously cloned PTH/PTHrP receptors, OK-O and R15B; and ii) primer RK-2 based on the 5' non-coding region of HPG1. H-26 was used as the reverse primer for both reactions. Southern blot and restriction map analyses

- 25 -

confirmed the expected size of the amplified DNA encoding the human PTH/PTHrP receptor. The blunt-ended PCR products encoding the 5' end of the human PTH/PTHrP were cloned into pcDNAI using the dephosphorylated EcoRV sites. Sequence analysis of each PCR clone confirmed their 5' nucleotide difference due to the difference in forward primer sequence, but revealed otherwise identical sequences. Nucleotide sequencing of both strands of the human PTH/PTHrP receptor cDNA revealed an open reading frame encoding a 593-amino acid protein (Fig. 6, SEQ ID NO.:4).

The full-length human kidney PTH/PTHrP receptor cDNA, HKrk, was constructed using the BamHI/PvuII fragment of PCR clone #2 and HK-2. Using the full-length cDNA encoding the human PTH/PTHrP receptor, Northern blot analysis of total RNA (~10 µg/lane) from human kidney and SaOS-2 cells revealed one major hybridizing DNA species of ~2.5 kb (Fig. 19). The XhoI digest of normal human genomic DNA, when probed with the same full-length cDNA (Fig. 20), revealed one major hybridizing species of about 5.5 kb, and two DNA species of 4 and 8 kb which weakly hybridized. These data suggest that the human PTH/PTHrP receptor is the product of a single gene. This full-length clone was then transiently expressed in COS-7 cells for functional and biological characterization by the methods cited above.

Comparison of the human receptor with the opossum kidney PTH/PTHrP receptor and the rat bone PTH/PTHrP receptor, revealed 81% and 91% amino acid sequence identity, respectively, and consequently a very similar hydrophobicity plot (Fig. 8). All extracellular cysteines including the two cysteine residues in the presumed signal peptide are conserved, as are all potential, extracellular

- 26 -

N-glycosylation sites. A number of the amino acids which were not identical between the human kidney and rat bone PTH/PTHr receptors were found to be conserved between the human and the opossum receptors. These conserved amino acids include an Arg to Leu at 51, an Arg to Trp at 58, an Arg to His at 262, an Asp to His at 358, an Ile to Thr at 422, and a Thr to Leu at 427.

#### Biological Characterization

Functional characterization of the biological properties of the opossum and rat PTH/PTHrP receptors was performed in transiently transfected COS cells by a radioreceptor assay technique using both  $^{125}\text{I}$ -PTHrP and  $^{125}\text{I}$ -NlePTH as radioligands, and by bioassays that measure ligand-stimulated cAMP accumulation, increase in intracellular free calcium, and stimulation of inositol phosphate metabolism, by the methods cited above.

Fig. 9 demonstrates that COS cells expressing OK-H bind  $^{125}\text{I}$ -PTHrP. These data also demonstrate that binding of PTHrP is inhibited when intact PTH (1-34) or PTH analogues which are shortened at their amino terminus (i.e. the 3-34 and 7-34 analogues, which contain Nle substitutions for methionine at positions 8 and 18 and a tyrosine substitution for phenylalanine at position 34) are used as competitors for binding. Similarly, binding of  $^{125}\text{I}$ -NlePTH to COS cells expressing OK-H was inhibited when PTHrP or PTHrP fragments were used as competitors. These data indicate that PTH and PTHrP both bind to the receptor encoded by OK-H.

Fig. 10 demonstrates that COS cells expressing OK-H increase their concentration of intracellular free calcium when exposed to NlePTH, but to a smaller extent (mean = 39 nm), or not at all, when compared to COS cells expressing OK-O or R15B receptors (Fig. 12 and Fig. 14) and stimulated with NlePTH. Unlike COS cells expressing

- 27 -

OK-O or R15B, COS cells expressing OK-H do not show a detectable increase in metabolism of inositol phosphate when stimulated with NlePTH (Fig. 15).

Fig. 11 demonstrates that COS cells expressing OK-  
5 O bind  $^{125}\text{I}$ -PTHrP. These data also demonstrate that binding of PTHrP is inhibited when intact PTH (1-34) or PTH analogues which are shortened at their amino terminus (i.e. the 3-34 and 7-34 analogues, which contain Nle  
10 substitutions for methionine at positions 8 and 18 and a tyrosine substitution for phenylalanine at position 34) are used as competitors for binding. Similarly, binding of  $^{125}\text{I}$ -NlePTH to COS cells expressing OK-H was inhibited when PTHrP or PTHrP fragments were used as competitors. These data indicate that PTH and PTHrP both bind to the  
15 receptor encoded by OK-O.

Fig. 12 demonstrates that COS cells expressing OK-O increase their concentration of intracellular free calcium and their rate of inositol phosphate metabolism after stimulation with NlePTH and PTHrP (Fig. 15).

Fig. 13 demonstrates that COS cells expressing  
20 R15B bind  $^{125}\text{I}$ -PTHrP. These data also demonstrate that binding of PTHrP is inhibited when intact PTH (1-34) or PTH analogues which are shortened at their amino terminus (i.e. the 3-34 and 7-34 analogues, which contain Nle  
25 substitutions for methionine at positions 8 and 18 and a tyrosine substitution for phenylalanine at position 34) are used as competitors for binding. Similarly, binding of  $^{125}\text{I}$ -NlePTH to COS cells expressing OK-H was inhibited when PTHrP or PTHrP fragments were used as competitors.  
30 These data indicate that PTH and PTHrP both bind to the receptor encoded by R15B.

Fig. 14 demonstrates that COS cells expressing R15B increase their concentration of intracellular calcium to an extent similar to stimulated COS cells  
35 expressing OK-O.

- 28 -

Fig. 15 demonstrates that COS cells expressing R15B or OK-O increase their rate of phosphatidyl inositol hydrolysis, as evidenced by the rapid increase in inositol trisphosphate ( $IP_3$ ) and inositol bisphosphate ( $IP_2$ ) accumulation after stimulation of the cells with NlePTH or PTHrP. Conversely, COS cells expressing OK-H did not show any detectable increase in inositol trisphosphate and inositol bisphosphate accumulation after stimulation with NlePTH or PTHrP. These data suggest that the PTH receptor encoded by R15B and OK-O is coupled to phospholipase C, presumably through  $G_p$ . Since the only difference between OK-O and OK-H is in the cytoplasmic C-terminal tail, these data strongly suggest that the C-terminus of the PTH receptor encoded by OK-O and R15B is involved in the activation of phospholipase C.

Fig. 16 demonstrates that COS cells expressing R15B and OK-H increase cAMP accumulation after stimulation with NlePTH. Similar results were obtained in COS cells expressing OK-O. No cAMP stimulation was detected in COS cells transfected with the cDM8 vector alone. These data suggest that PTH receptor coupling to adenylate cyclase does not require the full length C-terminal cytoplasmic tail of the receptor.

These data demonstrate that all three PTH/PTHrP receptors cloned from both OK and ROS cell cDNA libraries bind the amino-terminal ligands of both peptides equivalently. Activation of all these receptors by ligand stimulates adenylate cyclase (as measured by increased intracellular cAMP), presumably through activation of one class of guanine nucleotide binding proteins (G-proteins). G-proteins have a trimeric peptide structure in which one of the subunits, alpha, is distinct, and the other two, beta and gamma, are identical or highly homologous. One of these G-proteins

- 29 -

(G<sub>s</sub>) contains G-alpha-"stimulatory" (G-alpha-s) which is involved in the activation of adenylate cyclase.

Binding of ligand to OK-O and R15B, but not to OK-H, also increases intracellular free calcium and stimulates metabolism of inositol phosphate. These properties strongly suggest that activation of both OK-O and R15B receptors by ligand results in stimulation of a second intracellular effector, phospholipase C. The coupling mechanism between these activated receptors and phospholipase C is likely to be a G-protein which is distinct from G<sub>s</sub>. In contrast, the properties of the activated OK-H receptor which is truncated at the carboxy terminus, suggest that it may not activate phospholipase C, or that it activates phospholipase C inefficiently.

The biochemical role of the carboxy-terminal tail of the PTH/PTHrP receptor was further investigated by the construction of a carboxy-terminally-truncated rat receptor, R480, by standard PCR technology using R15B as a template and an upstream primer containing a stop codon inserted at position 481. Briefly, the upstream primer was a synthetic oligonucleotide based on nucleotides 1494-1513 of the rat cDNA sequence (see Fig. 3; SEQ ID NO.: 3) to which a stop codon and an XbaI cloning site were added. Thirty PCR cycles were carried out, each cycle consisting of 1 min at 92°C for denaturation, 1 min at 60°C for annealing, and 1 min at 72°C for extension. The product was cut with NsiI and XbaI and purified by gel electrophoresis. R15B was sequentially digested with XbaI and NsiI, and the purified PCR product was then ligated into the XbaI-NsiI cut R15B vector. The resulting plasmid, R480, was amplified in bacteria and sequenced.

R480 encodes 480 amino acids that are identical to those in the 591 amino acids receptor. This truncated cDNA was expressed in COS-7 cells (transient expression)

- 30 -

and in CHO cells (stable expression). Both COS-7 and CHO cells expressing the truncated receptor, R480, and the wild type receptor, RB, bind PTH(1-34) with equivalent affinities. When activated, R480 stimulates cAMP  
5 accumulation in COS7 and CHO cells as efficiently as does the wild type receptor. In contrast to the wild type receptor, R480 did not mediate any increase in  $[Ca^{2+}]_i$  when stimulated by PTH in either the COS-7 cells or the CHO cells. These data indicate that the molecular  
10 requirements for activation of phospholipase C and adenylate cyclase by PTH/PTHrP receptor are distinct from each other, and point to a major role of the carboxy-terminal tail of the PTH/PTHrP receptor in coupling to phospholipase C but not to adenylate cyclase. Of course,  
15 it is also possible that activated PTH/PTHrP receptors may activate additional G-proteins and/or intracellular effector molecules.

Analysis of COS-7 cells transfected with the cloned human PTH/PTHrP receptor demonstrated that  
20 radiolabelled PTH(1-34) and PTHrP(1-36) (~200,000 cpm) bound to the expressed receptors with similar efficiency (specific binding:  $10.1 \pm 3.7\%$  and  $7.6 \pm 6.0\%$ , respectively) to that observed for COS-7 cells expressing R15B (specific binding:  $8.1 \pm 3.5\%$  and  $7.1 \pm 4.1\%$ ,  
25 respectively). The expressed human PTH/PTHrP receptors bound PTH(1-34) with 2-fold higher apparent  $K_d$  than did the rat bone PTH/PTHrP receptor: ~5 nM versus ~10 nM (Fig. 17). However, despite their high degree of amino acid homology, the two receptors showed significant  
30 differences in affinity for PTH(3-34) and PTH(7-34). PTHrP(1-36) displayed a 2- to 4-fold lower affinity for the human PTH/PTHrP receptor than for the rat receptor (~35 nM for HKrk versus ~10 nM for R15B) which appeared more pronounced when PTHrP(1-36) was used as radioligand.  
35 The affinities for PTH(3-34) and PTH(7-34) were 7- and

- 31 -

35-fold higher with the expressed HKrK than with R15B (~7 nM versus ~45 nM for PTH(3-34), respectively; ~60 nM versus ~2000 nM for PTH(7-34), respectively). In COS-7 cells expressing either receptor, both PTH(1-34) and PTHrP(1-36) stimulated the increase in intracellular free calcium and cAMP accumulation to the same extent (Fig. 18).

#### Relationship of PTH/PTHrP receptors

The amino acid sequence of the human PTH/PTHrP receptor displays a very high degree of conservation compared to the bone PTH/PTHrP receptor from rat, a eutherian mammal, while its sequence identity with the PTH/PTHrP receptor with the opossum, a marsupial mammal, is less marked. Like the opossum kidney and the rat bone receptor, the human kidney receptor induces an increase in both intra-cellular cAMP and intracellular free calcium when challenged with either PTH or PTHrP. Despite the high degree of homology between the human PTH/PTHrP receptor and the opossum and rat homologs, the transiently expressed human receptor has some functional characteristics that are distinct from those of the rat bone receptor. These include a slightly higher affinity for PTH(1-34) and a significantly decreased affinity for PTHrP(1-36). Higher affinities were observed for PTH(3-34) and in particular for PTH(7-34), the affinity of which for the human receptor was about 35-fold higher in comparison to the rat bone receptor. These findings may have significant implications for the future development of PTH/PTHrP analogues, since they predict that species-specific tissues would be the appropriate tissues for testing the potency of antagonists (and agonists) *in vitro*.

#### Relationship of PTH/PTHrP receptors to other receptors

The biochemical properties of PTH and PTHrP receptors suggest that they are members of the class of

- 32 -

membrane receptor molecules known as G-protein-linked membrane receptors. The structural features of well-characterized G-protein receptors indicate that they all have at least seven regions of several consecutive  
5 hydrophobic amino acids, each of which regions is of sufficient length to span the plasma membrane.

One subfamily of G-protein-linked membrane receptors, termed the glycopeptide receptor subfamily, includes receptors that bind and are activated by  
10 glycopeptide hormones (thyroid-stimulating hormone, luteinizing hormone, follicle-stimulating hormone, and chorionic gonadotropin). All of these receptors are characterized by (1) extensive putative amino-terminal extracellular domains (greater than 300 amino acids) that  
15 are thought to contain some or all of the ligand-binding domains, and (2) considerable amino-acid homology, particularly in the seven putative transmembrane domains. A second subfamily, termed the adrenergic/muscarinic subfamily, includes receptors that are activated by small  
20 ligands, such as the catecholamines, neuromuscular transmitters, and retinol. These receptors are all characterized by relatively short (25-75 amino acids) putative amino-terminal extracellular domains, as well as considerable amino acid homology, particularly in the  
25 seven putative transmembrane domains. Activation of these receptors by their ligands appears to involve at least several of the multiple transmembrane domains, and does not appear to involve the amino-terminal portion of the receptors.

30 Several structural characteristics which can be deduced from the predicted amino acid sequence of the rat PTH/PTHrP receptor (Fig. 3) indicate that the PTH/PTHrP is a G-protein-linked receptor. The amino terminus shows characteristic features of a signal peptide, including a  
35 hydrophobic domain and the presence of three consecutive

- 33 -

leucine residues. This amino acid stretch of 20-28 amino acids may serve as a leader sequence, similar to the amino terminus preceding the extracellular domains of other glycoprotein receptors. There is also a cluster of  
5 seven hydrophobic segments which represent putative membrane-spanning domains (Fig. 19).

The predicted amino acid sequences of the opossum kidney, rat bone and human kidney PTH/PTHrP receptors indicate that they do not fit comfortably into either of  
10 these G-protein linked receptor subfamilies. Overall homology of the rat and human PTH/PTHrP receptors with the glycopeptide receptor and adrenergic/muscarinic subfamilies is approximately 10 to 20%, with a somewhat higher degree of homology within the transmembrane  
15 domains. The latter is to be expected because of the limited menu of hydrophobic amino acids that could occur in those regions. Twenty percent homology is far less than that found among the receptors generally accepted to be members of each of these subfamilies. Additionally,  
20 there are no portions of these sequences that have what could be characterized as intense homology (i.e., exactly matching amino acid sequences), even over limited regions.

Recent comparison with the newly characterized  
25 secretin and calcitonin receptors (Ishihara et al., EMBO J 10:1635, 1991; Lin et al., Science 254:1022, 1991) has revealed between 30 and 40% identity between these receptors and the PTH/PTHrP receptor. Although the PTH/PTHrP receptor is more than 100 amino acids longer  
30 than the calcitonin receptor, there is an ~32% identity between the amino acid sequences of the opossum kidney PTH/PTHrP receptor (SEQ ID NO NO.:2) and porcine kidney calcitonin receptor (GenBank accession no. M74420). A stretch of 17 out of 18 amino acids in the putative  
35 transmembrane domain VII are identical. Also, two out of

- 34 -

four N-linked glycosylation sites and the position of seven out of eight potentially extracellular cysteines are conserved. Major differences between the two receptors appear to lie in their NH<sub>2</sub>-terminal and COOH-terminal domains. Comparison of amino acid sequences of the rat secretin receptor (GenBank accession no. X59132) and the human PTH/PTHrP receptor indicates that there is a 43% identity between these two receptors, with a stretch of 21 out of 25 amino acids of the putative transmembrane domain VII being identical. The similarity between the PTH/PTHrP, calcitonin and secretin receptors suggests that they represent a new family of seven transmembrane-spanning G protein-coupled receptors that activate adenylate cyclase. Given the amino acid sequences of these receptors, those skilled in the art would be able to compare these sequences for regions of identity which would be useful in the design of nucleic acid probes which could then be used for the identification and isolation of other receptors which would belong to this family.

#### Deposit of Clones

Under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purpose of Patent Procedure, the cDNA expression plasmids R15B, OK-O, and OK-H; the phage HPG1; and a plasmid (termed 8A6) containing part of the human clone have been deposited with the American Type Culture Collection (ATCC), where they bear the respective accession numbers ATCC No. 68571, 68572, 68573, 40998 and 68570. Applicants' assignee, The General Hospital Corporation, represents that the ATCC is a depository affording permanence of the deposits and ready accessibility thereto by the public if a patent is granted. All restrictions on the availability to the

- 35 -

public of the material so deposited will be irrevocably removed upon the granting of a patent. The material will be available during the pendency of the patent application to one determined by the Commissioner to be  
5 entitled thereto under 37 CFR 1.14 and 35 U.S.C. 122. The deposited material will be maintained with all the care necessary to keep it viable and uncontaminated for a period of at least five years after the most recent request for the furnishing of a sample of the deposited  
10 plasmid, and in any case, for a period of at least thirty (30) years after the date of deposit or for the enforceable life of the patent, whichever period is longer. Applicants' assignee acknowledges its responsibility to replace the deposits should the  
15 depository be unable to furnish a sample when requested due to the condition of the deposit.

#### POLYPEPTIDES

Polypeptides according to the invention include the opossum and rat and human parathyroid hormone  
20 receptors as shown in Figs. 1-3 and 6, respectively, and any other naturally-occurring receptor which can be produced by methods analogous to those used to clone and express these receptors, or by methods utilizing as a probe all or part of one of the sequences described  
25 herein. In addition, any analog or fragment of a PTH receptor capable of binding to a parathyroid hormone or a parathyroid hormone-related protein is within the invention.

Specific receptor analogs of interest include  
30 full-length or partial receptor proteins having an amino acid sequence which differs only by conservative amino acid substitutions: for example, substitution of one amino acid for another of the same class (e.g., valine for glycine; arginine for lysine, etc.), or by one or  
35 more non-conservative amino-acid substitutions,

- 36 -

deletions, or insertions located at positions which do not destroy the receptor's ability to bind to parathyroid hormone or parathyroid hormone-related protein.

Specific receptor fragments of particular interest include, but are not limited to, portions of the receptor deduced to be extracellular from the primary amino acid sequence, using a hydrophobicity/hydrophilicity calculation such as the Chou-Fasman method (see, e.g., Chou and Fasman, Ann. Rev. Biochem. 47:251, 1978).

10 Hydrophilic domains, particularly ones surrounded by hydrophobic stretches (e.g., transmembrane domains) of at least 10 amino acids, present themselves as strong candidates for extracellular domains. Fig. 21 illustrates a predicted arrangement of extracellular, 15 intracellular, and transmembrane domains of one PTH receptor.

Examples of specific PTH receptor fragments include those with the following amino acid sequences (shown as standard single-letter symbols), derived from 20 the deduced amino acid sequence of the R15B clone:

Extracellular domains:

- RP-1: TNETREREVFDRLGMIYTVG (SEQ ID NO.: 5)  
RP-2: VLYSGFTLDEAERLTEEEL (SEQ ID NO.: 6)  
RP-3: VTFFLYFLATNYWILVEG (SEQ ID NO.: 7)  
25 RP-4: Y-RATLANTGCWDLSSGHKKWIIQVP (SEQ ID NO.: 8)  
RP-5: PYTEVSGTLWQIQMHYEM (SEQ ID NO.: 9)  
RP-6: DDVFTKEEQIFLLHRAQA (SEQ ID NO.: 10)

Intracellular domains:

- RPi-7: FRRLHCTRNY (SEQ ID NO.: 11)  
30 RPi-8: EKLYLWGFTL (SEQ ID NO.: 12)  
RPi-9: VLATKLRETNAGRCDTRQQYRKLLK (SEQ ID NO.: 13)

These fragments were synthesized and purified by HPLC according to the method of Keutmann et al., (Endocrinology 117: 1230, 1984).

- 37 -

EXPRESSION OF POLYPEPTIDES

Polypeptides according to the invention may be produced by expression from a recombinant nucleic acid having a sequence encoding part or all of a cell receptor of the invention, using any appropriate expression system: e.g., transformation of a suitable host cell (either prokaryotic or eukaryotic) with the recombinant nucleic acid in a suitable expression vehicle (e.g., pCDNAI). The precise host cell used is not critical to the invention; however, in the case wherein the polypeptides of the invention include all or part of the PTH/PTHrP receptor, the following host cells are preferred: COS cells, LLC-PK1 cells, OK cells, AtT20 cells, and CHO cells. The method of transfection and the choice of expression vehicle will depend on the host system selected. Mammalian cell transfection methods are described, e.g., in Ausubel et al. (Current Protocols in Molecular Biology, John Wiley & Sons, New York, 1989); expression vehicles may be chosen from those discussed, e.g., in Cloning Vectors: A Laboratory Manual (P.H. Pouwels et al., 1985, Supp. 1987). Stably transfected cells are produced via integration of receptor DNA into the host cell chromosomes. Suitable DNAs are inserted into pCDNA, pCDNAI-Neo, or another suitable plasmid, and then cells are transfected with this plasmid with or without cotransfection with psV-2-Neo, or psV-2-DHFR by standard electroporation, calcium phosphate, and/or DEAE/Dextran techniques. Selection of transfected cells is performed using progressively increasing levels of G418 (Geneticin, GIBCO), and if necessary, methotrexate.

DNA sequences encoding the polypeptides of the invention can also be expressed in a prokaryotic host cell. DNA encoding a cell receptor or receptor fragment is carried on a vector operably linked to control signals capable of effecting expression in the prokaryotic host.

- 38 -

If desired, the coding sequence may contain, at its 5' end, a sequence encoding any of the known signal sequences capable of effecting secretion of the expressed protein into the periplasmic space of the host cell, thereby facilitating recovery of the protein and subsequent purification. Prokaryotes most frequently used are various strains of E. coli; however, other microbial strains may also be used. Plasmid vectors are used which contain replication origins, selectable markers, and control sequences derived from a species compatible with the microbial host. For example, E. coli may be transformed using derivatives of pBR322, a plasmid constructed by Bolivar et al. (Gene 2: 95, 1977) using fragments derived from three naturally-occurring plasmids, two isolated from species of Salmonella, and one isolated from E. coli. pBR322 contains genes from ampicillin and tetracycline resistance, and thus provides multiple selectable markers which can be either retained or destroyed in constructing the desired expression vector. Commonly used prokaryotic control sequences (also referred to as "regulatory elements") are defined herein to include promoters for transcription initiation, optionally with an operator, along with ribosome binding site sequences. Promoters commonly used to direct protein expression include the beta-lactamase (penicillinase), the lactose (lac) (Chang et al., Nature 198: 1056, 1977) and the tryptophan (Trp) promoter systems (Goeddel et al., Nucl. Acids Res. 8: 4057, 1980) as well as the lambda-derived P<sub>L</sub> promoter and N-gene ribosome binding site (Simatake et al., Nature 292:128, 1981).

The nature of the cell receptor proteins of the invention is such that, upon expression within a cell, it is moved to the cellular membrane and partially through the membrane, so that part of it remains embedded in the

- 39 -

membrane, part extends outside the cell, and part remains within the cell. Transformed cells bearing such embedded cell receptors may themselves be employed in the methods of the invention, or the receptor protein may be  
5 extracted from the membranes and purified.

Expression of peptide fragments lacking the hydrophobic portions of the protein responsible for anchoring the intact protein in the cellular membrane would not be expected to become embedded in the membrane;  
10 whether they remain within the cell or are secreted into the extracellular medium depends upon whether or not a mechanism promoting secretion (e.g., a signal peptide) is included. If secreted, the polypeptide of the invention can be harvested from the medium; if not, the cells must  
15 be broken open and the desired polypeptide isolated from the entire contents of the cells. Specific examples of polypeptides which might be expressed include, without limitation:

1) Amino-terminal portion comprising amino acids  
20 1-192, including the putative leader sequence, of the rat bone PTH/PTHrP receptor as shown in Fig. 3.

2) Amino-terminal portion comprising amino acids 27-192, excluding the putative leader sequence, of the rat bone PTH/PTHrP receptor as shown in Fig. 3.

25 3) The full-length PTH/PTHrP receptor from rat bone, as shown in Fig 3.

4) RP-1 (as described above).

5) RP-2 (as described above).

The polypeptide of the invention can be readily  
30 purified using affinity chromatography. Antibodies to these polypeptides, or the receptor specific ligands, (e.g., the hormones PTH and PTHrP for the PTH/PTHrP receptor) may be covalently coupled to a solid phase support such as Sepharose 4 CNBr-activated sepharose  
35 (Pharmacia), and used to separate the polypeptide of the

- 40 -

invention from any contaminating substances. Typically 1 mg of ligand or antibody will be incubated with CNBr-activated sepharose at 4°C for 17-20 h (with shaking). The sepharose is rinsed with 1 M Tris HCL (pH8) to block excess active sites. The sepharose-PTH, sepharose-PTHrP, or sepharose-antibody is then incubated with the crude polypeptide in phosphate-buffered saline (pH 7.4) at 4°C for 2 h (with shaking). The sepharose is then typically packed in a column, thoroughly washed with PBS (typically 10 times the column volume), and eluted with dilute HCl in H<sub>2</sub>O (pH 1.85). The eluate may then be concentrated by lyophilization and its purity checked, for example, by reverse phase HPLC.

#### ANTI-CELL RECEPTOR ANTIBODIES

Cell receptor or receptor fragments of the invention may be used to generate antibodies by any conventional method well known to those skilled in the art, including those which generate polyclonal antibodies and those which generate monoclonal antibodies. For example, the deduced amino acid sequence of the PTH receptor reveals a protein structure that appears to have several transmembrane (i.e., hydrophobic) domains interspersed with presumably extracellular and intracellular regions (see Fig. 21) analogous to those found in other G protein-linked receptors. This information can be used to guide the selection of regions of the receptor protein which would be likely to be exposed on the cell surface, and thus would be presented to antibodies in vivo. A short peptide representing one or more of such regions may be synthesized (e.g., chemically or by recombinant DNA techniques) and used to immunize an animal (e.g., a rabbit or a mouse) to generate polyclonal or monoclonal antibodies. For example, certain of the peptides of the PTH/PTHrP receptor listed above (RP-1, RP-5 and RP-6) have been

- 41 -

chemically synthesized using standard techniques and used to generate polyclonal antibodies in rabbits by the following procedure:

A preparation of a given peptide emulsified with complete Freund's Adjuvant is injected intradermally into rabbits. Booster injections are emulsified in or complete adjuvant and injected at monthly intervals.

Antibody titer is assessed using either of two methods. First, serial dilutions of the antiserum in 1% normal rabbit serum are incubated with  $^{125}\text{I}$ -labelled PTH/PTHrP receptor fragment by standard methods (e.g., see Segre et al., supra) for 24 h at 4° C. The bound  $^{125}\text{I}$ -PTH/PTHrP receptor fragments are separated from unbound by addition of 100  $\mu\text{l}$  of second antibody (anti-rabbit IgG, Sigma) diluted 1:20 and 1 ml of 5% polyethylene glycol, followed by centrifugation at 2000 rpm for 30 min. at 4° C. The supernatant is removed and the pellet analyzed for radioactivity in a  $\gamma$ -counter. In the second method, cell lines expressing either native (e.g., ROS 17/2.8, OK, SaOS-02 cells) or recombinant (COS cells or CHO cells transfected with R15B, OK-O or OK-H) PTH/PTHrP receptors are incubated with serially diluted antibody at 4°C, 20°C or 37°C for 1- 4 h. The cells are rinsed with PBS (x3) and incubated for 2 h at 4°C with  $^{125}\text{I}$ -labelled (NEN, Dupont) or FITC-labelled (Sigma) second antibodies. After rinsing (x3 with PBS), the cells were either lysed with 0.1 M NaOH and counted in  $\gamma$ -counter (if  $^{125}\text{I}$ -labelled second antibody was used) or fixed with 1% paraformaldehyde and examined by fluorescent microscopy (if FITC-labelled second antibody was used).

Another method for producing antibodies utilizes as antigen the intact cell receptor protein of the invention expressed on the surface of cells (e.g., mammalian cells, such as COS cells, transfected with DNA

- 42 -

encoding the receptor). Such cells are prepared by standard techniques, e.g., by the DEAE-dextran transfection method, using a vector encoding and capable of directing high-level expression of the cell receptor.

- 5 Such cells may be used to generate polyclonal or monoclonal antibodies. For example, monoclonal antibodies specific for the PTH/PTHrP receptor may be produced by the following procedure:

- Intact COS cells expressing high levels of rat  
10 recombinant PTH receptors on the cell surface are injected intraperitoneally (IP) into Balb-c mice (Charles River Laboratories, Willmington, MA). The mice are boosted every 4 weeks by IP injection, and are hyperimmunized by an intravenous (IV) booster 3 days  
15 before fusion. Spleen cells from the mice are isolated and are fused by standard methods to myeloma cells. Hybridomas are selected in standard hypoxanthine/aminopterin/thymine (HAT) medium, according to standard methods. Hybridomas secreting antibodies  
20 which recognize the PTH receptor are initially identified by screening with cell lines which naturally express abundant copies of the PTH-receptor per cell (such as ROS17/2.8 or OK cells), using standard immunological techniques. Those hybridomas which produce antibodies  
25 capable of binding to the PTH receptor are cultured and subcloned. Secondary screening with radioreceptor and cAMP stimulation assays can then be performed to further characterize the monoclonal antibodies (see below).

#### SCREENING FOR PTH RECEPTOR ANTAGONISTS AND AGONISTS

- 30 The polypeptides and antibodies of the invention and other compounds may be screened for PTH-competition and for antagonistic or agonistic properties using the assays described herein.

- In one example, those antibodies that recognize  
35 the PTH receptor on the intact cells are screened for

- 43 -

their ability to compete with PTH or PTHrP for binding to a PTH/PTHrP receptor. Cells expressing PTH receptor on the cell surface are incubated with the  $^{125}\text{I}$ -PTH analog,  $^{125}\text{I}$ -NlePTH or  $^{125}\text{I}$ -PTHrP in the presence or absence of the polyclonal or monoclonal antibody to be tested, for 4 h at 15°C. The antibody used may be from crude antiserum, cell medium, or ascites, or in purified form. After incubation, the cells are rinsed with binding buffer (e.g., physiological saline), lysed, and quantitatively analyzed for radioactivity using a gamma-counter. Antibodies that reduce binding of the PTH analog to the PTH receptor are classified as competitive; those which do not are noncompetitive.

Compounds, including antibodies and polypeptides, may be screened for their agonistic or antagonistic properties using the cAMP accumulation, intracellular calcium, and/or inositol phosphate assays described above. Cells expressing PTH receptor on the cell surface are incubated with PTH, PTH-receptor antibody, or a combination of both, for 5 - 60 minutes at 37°C, in the presence of 2 mM IBMX (3-isobutyl-1-methyl-xanthine, Sigma, St. Louis, MO). Cyclic AMP accumulation is measured by specific radio-immunoassay, as described above. A compound that competes with PTH for binding to the PTH receptor, and that inhibits the effect of PTH on cAMP accumulation, is considered a competitive PTH antagonist. Conversely, a compound that does not compete for PTH binding to the PTH receptor, but which still prevents PTH activation of cAMP accumulation (presumably by blocking the receptor activation site) is considered a non-competitive antagonist. A compound that competes with PTH for binding to the PTH receptor, and which stimulates cAMP accumulation in the presence or absence of PTH, is a competitive agonist. A compound that does not compete with PTH for binding to the PTH receptor but

- 44 -

which is still capable of stimulating cAMP accumulation in the presence or absence of PTH, or which stimulates a higher accumulation than that observed by PTH alone, would be considered a non-competitive agonist.

##### 5 USE

The polypeptides, antibodies, and other compounds of the invention are useful for the diagnosis, classification, prognosis, and/or treatment of disorders which may be characterized as related to the interaction  
10 between a cell receptor of the invention and its specific ligand. For example, some forms of hypercalcemia and hypocalcemia are related to the interaction between PTH and PTHrP and the PTH/PTHrP receptor(s). Hypercalcemia is an condition in which there is an abnormal elevation  
15 in serum calcium level; it is often associated with other diseases, including hyperparathyroidism, osteoporosis, carcinomas of the breast, lung and prostate, epidermoid cancers of the head and neck of the esophagus, multiple myeloma, and hypernephroma. Hypocalcemia, a condition in  
20 which the serum calcium level is abnormally low, may result from a deficiency of effective PTH, e.g., following thyroid surgery.

In a first example, the compounds of the invention are used to manufacture diagnostic agents which are used  
25 as diagnostic tools to diagnose hypercalcemia and to distinguish between hypercalcemic conditions, i.e., to differentiate hypercalcemia mediated by PTH or PTHrP (e.g., hyperparathyroidism and humoral hypercalcemia of malignancy), from hypercalcemia associated with diseases  
30 which do not involve these factors (e.g., local osteolytic hypercalcemia mediated by the presence of metastatic tumor cells in direct contact with bone, and certain rare types of malignancy-related hypercalcemias mediated by an increase of humoral factors, such as  
35 osteoclast activating factor (interleukin), lymphotoxin,

- 45 -

calcitriol, type E prostaglandins, and vitamin D-like sterols).

In one method of diagnosis, serum total and/or ionized calcium levels are measured by standard techniques before and after the administration of the PTH or PTHrP antagonists of the invention. PTH or PTHrP related hypercalcemias would be detectable as a decrease in serum calcium levels following administration of the antagonist of the invention. In contrast, for hypercalcemic conditions mediated by factors other than PTH or PTHrP, the serum calcium levels would remain unchanged even after administration of the antagonist.

Another diagnostic application of the invention permits measurement of the level of PTH or PTHrP in a biological sample in order to diagnose PTH or PTHrP related tumors, e.g., tumors which are associated with humoral hypercalcemia of malignancy, and for monitoring the levels of PTH or PTHrP during cancer therapy. This method involves assaying binding of the recombinant parathyroid hormone receptor of the invention to PTH or PTHrP present in a tissue sample, using the binding assay described herein. The level of binding may be determined directly (e.g., by using radioactively labelled PTH receptor, and assaying the radioactivity bound to endogenous PTH). Alternatively, binding of PTH receptor to the sample (e.g., a tissue section) may be followed by staining of the tissue sections with an antibody specific for the PTH receptor, using standard immunological techniques (Chin et al., Hybridoma 5:339, 1986).

In a third diagnostic approach, one could stably transfect cell lines (by the methods described in Ausubel et al., Current Protocols in Molecular Biology, Wiley Publishers, New York, 1987) with a PTH receptor gene linked to an appropriate promoter (e.g., the metallothionine promoter). Alternatively, the PTH/PTHrP

- 46 -

receptor could be expressed from a eukaryotic vector, i.e., pcDNAI, and cotransfected with a mutant DHFR gene that will allow further gene amplification via methotrexate selection (Simonsen et al., Proc. Natl. Acad. Sci., 80:2495-2499, 1983). Such high-level expression of the gene produces an immortal cell line which is oversensitive to PTH or PTHrP. Such cells provide a particularly useful tool for detecting serum blood levels of PTH or PTHrP. Such a cell line may be used for diagnosis of conditions involving elevated PTH or PTHrP levels (e.g., those described above) or for conditions involving unusually low levels of PTH or PTHrP (e.g., those described above). Such a cell line is also useful for monitoring the regression or increase of PTH or PTHrP levels during therapy for hypercalcemia or hypocalcemia, respectively.

A patient who is suspected of being hypercalcemic may be treated using the compounds of the invention. Rapid intervention is important because symptoms may appear abruptly and, unless reversed, can be fatal. In one application, serum calcium levels are stabilized by an immediate course of treatment which includes antagonists of PTH or PTHrP. Such antagonists include the compounds of the invention which have been determined (by the assays described herein) to interfere with PTH receptor-mediated cell activation. To administer the antagonist, the appropriate antibody or peptide (is used in the manufacture of a medicament, generally by being formulated in an appropriate carrier such as physiological saline, and administered intravenously, at a dosage that provides adequate competition for PTH or PTHrP binding to the PTH receptor (e.g., a dosage sufficient to lower the serum calcium level to below 10 mg/dl). Typical dosage would be 1 ng to 10 mg of the antibody or peptide per kg body weight per day.

- 47 -

Treatment may be repeated as necessary for long term maintenance of acceptable calcium levels (i.e., levels < 10.1 mg/dl). This may be necessary for acute treatment of an underlying disease condition triggering  
5 hypercalcemia; or it may be used, e.g., for chronic treatment of conditions such as osteoporosis.

In another application, the compounds of the invention which have been characterized, according to the methods of the invention, to be agonists are used  
10 therapeutically to treat hypocalcemia: e.g., that resulting from the partial or complete surgical removal of the parathyroid glands. Agonists may be formulated in a suitable carrier (e.g., physiological saline) and are preferably administered intravenously in a dosage that  
15 causes a rise in serum calcium to an acceptable level (i.e., approximately 8 mg/dl). A useful dosage range would be 1 ng to 10 mg of the agonist per kg body weight per day. Treatment may be repeated as necessary to maintain suitable serum calcium levels; long term  
20 treatment may be necessary for patients who have undergone parathyroid gland removal.

The nucleic acids of the invention may also be used therapeutically. Oligonucleotides which are antisense to PTH receptor mRNA (or nucleic acid  
25 constructs which express RNA that is antisense to PTH receptor mRNA) may be utilized as an anticancer therapy. This approach is useful, e.g., for hypercalcemias resulting from a genomic rearrangement or amplification which increases the amount or activity of PTH receptor,  
30 PTH or PTHrP. The method would involve introduction of the antisense oligonucleotide into the tumor cells *in vivo*. The antisense strand hybridizes with endogenous PTH receptor mRNA, interfering with translation of the protein, thereby reducing production of PTH receptor in  
35 such cells, and reducing PTH/PTHrP-associated neoplastic

- 48 -

growth. Methods for antisense design and introduction into host cells are described, for example, in Weinberg et al., U.S. Patent No. 4,740,463, herein incorporated by reference. The biochemical characterization of the OK-H, OK-O and R15B PTH/PTHrP receptors of the invention demonstrate that the two transduction pathways now known to be triggered by the interaction of PTH with its receptor are distinct and may be separated. The predicted amino acid sequences of these receptors indicate that OK-H, which does not appear to activate inositol phosphate metabolism to any detectable degree, is 70 amino acids shorter at the carboxy-terminus than OK-O or R15B. By using the sequences of the invention and the information disclosed herein, one could clone and then alter (e.g. by site-directed mutagenesis) PTH/PTHrP receptor genes from any species to generate PTH/PTHrP receptors which do not activate phospholipase C. This could potentially allow the separation of different PTH-mediated actions, including bone resorption and bone formation, and could of great importance for the treatment of various bone disorders such as osteoporosis.

Nucleic acids of the invention which encode a PTH receptor may also be linked to a selected tissue-specific promoter and/or enhancer and the resultant hybrid gene introduced, by standard methods (e.g., as described by Leder et al., U.S. Patent No. 4,736,866, herein incorporated by reference), into an animal embryo at an early developmental stage (e.g., the fertilized oocyte stage), to produce a transgenic animal which expresses elevated levels of PTH receptor in selected tissues (e.g., the osteocalcin promoter for bone). Such promoters are used to direct tissue-specific expression of the PTH receptor in the transgenic animal. The form of PTH receptor utilized can be one which encodes a PTH receptor similar to that of the animal species used, or

- 49 -

it can encode the PTH receptor homolog of a different species. In one particular example, transgenic chickens are engineered to express the PTH receptor from a promoter which directs high-level expression in chicken  
5 oviducts. Such an animal is expected to produce eggs with higher calcium content, and thus harder shells.

Other Embodiments

Other embodiments are within the following claims. For example, the nucleic acid of the invention includes  
10 genes or cDNAs or RNAs originally isolated from any vertebrate species, including birds or mammals such as marsupials, rodents, or humans. The high degree of homology demonstrated for the PTH receptors from such diverse species as opossum, rat, and human indicates that  
15 the methods of isolating PTH receptors disclosed herein will be broadly applicable to the isolation of related cell receptors from a wide variety of species.

- 50 -

COMPUTER SUBMISSION OF DNA AND AMINO ACID SEQUENCES

## (1) GENERAL INFORMATION:

- (i) APPLICANT: Segre, Gino V.  
Kronenberg, Henry M.  
Abou-Samra, Abdul-Badi  
Juppner, Harald  
Potts, John T., Jr.  
Schipani, Ernestina
- (ii) TITLE OF INVENTION: PARATHYROID HORMONE RECEPTOR AND DNA  
ENCODING SAME
- (iii) NUMBER OF SEQUENCES: 3
- (iv) CORRESPONDENCE ADDRESS:
- (A) ADDRESSEE: Fish & Richardson  
(B) STREET: 225 Franklin Street  
(C) CITY: Boston  
(D) STATE: Massachusetts  
(E) COUNTRY: U.S.A.  
(F) ZIP: 02110-2804
- (v) COMPUTER READABLE FORM:
- (A) MEDIUM TYPE: 3.5" Diskette, 1.44 Mb storage  
(B) COMPUTER: IBM PS/2 Model 50Z or 55SX  
(C) OPERATING SYSTEM: IBM P.C. DOS (Version 3.30)  
(D) SOFTWARE: WordPerfect (Version 5.0)
- (vi) CURRENT APPLICATION DATA:
- (A) APPLICATION NUMBER:  
(B) FILING DATE:  
(C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
- (A) APPLICATION NUMBER: 07/681,702  
(B) FILING DATE: April 5, 1991
- (viii) ATTORNEY/AGENT INFORMATION:
- (A) NAME: Paul T. Clark  
(B) REGISTRATION NUMBER: 30,162  
(C) REFERENCE/DOCKET NUMBER: 00786/071001
- (ix) TELECOMMUNICATION INFORMATION:
- (A) TELEPHONE: (617) 542-5070  
(B) TELEFAX: (617) 542-8906

- 51 -

(C) TELEX:

200154

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH:1862
- (B) TYPE:nucleic acid
- (C) STRANDEDNESS:double
- (D) TOPOLOGY:linear

(xi) SEQUENCE DESCRIPTION: SEQUENCE ID NO: 1:

TGGGCACAGC CACCCTGTTG GTAGTCCAGG GGCCAGCCCA CTGAGCTGGC ATATCAGCTG	60
GTGGCCCCGT TGGACTCGGC CCTAGGGAAC GGC GGCG ATG GGA GCG CCC CGG ATC	115
Met Gly Ala Pro Arg Ile	
1 5	
TCG CAC AGC CTT GCC TTG CTC CTC TGC TGC TCC GTG CTC AGC TCC GTC	163
Ser His Ser Leu Ala Leu Leu Leu Cys Cys Ser Val Leu Ser Ser Val	
10 15 20	
TAC GCA CTG GTG GAT GCC GAT GAT GTC ATA ACG AAG GAG GAG CAG ATC	211
Tyr Ala Leu Val Asp Ala Asp Asp Val Ile Thr Lys Glu Glu Gln Ile	
25 30 35	
ATT CTT CTG CGC AAT GCC CAG GCC CAG TGT GAG CAG CGC CTG AAA GAG	259
Ile Leu Leu Arg Arg Asn Ala Gln Ala Gln Cys Glu Gln Arg Leu Lys Glu	
40 45 50	
GTC CTC AGG GTC CCT GAA CTT GCT GAA TCT GCC AAA GAC TGG ATG TCA	307
Val Leu Arg Val Pro Glu Leu Ala Glu Ser Ala Lys Asp Trp Met Ser	
55 60 65 70	
AGG TCT GCA AAG ACA AAG AAG GAG AAA CCT GCA GAA AAG CTT TAT CCC	355
Arg Ser Ala Lys Thr Lys Lys Glu Lys Pro Ala Glu Lys Leu Tyr Pro	
75 80 85	
CAG GCA GAG GAG TCC AGG GAA GTT TCT GAC AGG AGC CGG CTG CAG GAT	403
Gln Ala Glu Glu Ser Arg Glu Val Ser Asp Arg Ser Arg Leu Gln Asp	
90 95 100	
GGC TTC TGC CTA CCT GAG TGG GAC AAC ATT GTG TGC TGG CCT GCT GGA	451
Gly Phe Cys Leu Pro Glu Trp Asp Asn Ile Val Cys Trp Pro Ala Gly	
105 110 115	
GTG CCC GGC AAG GTG GTG GCC GTG CCC TGC CCC GAC TAC TTC TAC GAC	499
Val Pro Gly Lys Val Val Ala Val Pro Cys Pro Asp Tyr Phe Tyr Asp	
120 125 130	
TTC AAC CAC AAA GGC CGA GCC TAT CGG CGC TGT GAC AGC AAT GGC AGC	547
Phe Asn His Lys Gly Arg Ala Tyr Arg Arg Cys Asp Ser Asn Gly Ser	
135 140 145 150	

- 52 -

TGG GAG CTG GTG CCT GGG AAC AAC CGG ACA TGG GCG AAT TAC AGC GAA	595
Trp Glu Leu Val Pro Gly Asn Asn Arg Thr Trp Ala Asn Tyr Ser Glu	
155 160 165	
TGT GTC AAG TTT CTG ACC AAC GAG ACC CGG GAA CGG GAA GTC TTT GAT	643
Cys Val Lys Phe Leu Thr Asn Glu Thr Arg Glu Arg Glu Val Phe Asp	
170 175 180	
CGC CTC GGA ATG ATC TAC ACT GTG GGC TAC TCC ATC TCT CTG GGC TCC	691
Arg Leu Gly Met Ile Tyr Thr Val Gly Tyr Ser Ile Ser Leu Gly Ser	
185 190 195	
CTC ACT GTG GCT GTG CTG ATT CTG GGT TAC TTT AGG AGG TTA CAT TGC	739
Leu Thr Val Ala Val Leu Ile Leu Gly Tyr Phe Arg Arg Leu His Cys	
200 205 210	
ACC CGA AAC TAC ATT CAC ATG CAT CTC TTC GTG TCC TTT ATG CTC CGG	787
Thr Arg Asn Tyr Ile His Met His Leu Phe Val Ser Phe Met Leu Arg	
215 220 225 230	
GCT GTA AGC ATC TTC ATC AAG GAT GCT GTG CTC TAC TCG GGG GTT TCC	835
Ala Val Ser Ile Phe Ile Lys Asp Ala Val Leu Tyr Ser Gly Val Ser	
235 240 245	
ACA GAT GAA ATC GAG CGC ATC ACC GAG GAG GAG CTG AGG GCC TTC ACA	883
Thr Asp Glu Ile Glu Arg Ile Thr Glu Glu Glu Leu Arg Ala Phe Thr	
250 255 260	
GAG CCT CCC CCT GCT GAC AAG GCG GGT TTT GTG GGC TGC AGA GTG GCG	931
Glu Pro Pro Pro Ala Asp Lys Ala Gly Phe Val Gly Cys Arg Val Ala	
265 270 275	
GTA ACC GTC TTC CTT TAC TTC CTG ACC ACC AAC TAC TAC TGG ATC CTG	979
Val Thr Val Phe Leu Tyr Phe Leu Thr Thr Asn Tyr Tyr Trp Ile Leu	
280 285 290	
GTG GAA GGC CTC TAC CTT CAC AGC CTC ATC TTC ATG GCT TTT TTC TCT	1027
Val Glu Gly Leu Tyr Leu His Ser Leu Ile Phe Met Ala Phe Phe Ser	
295 300 305 310	
GAG AAA AAG TAT CTC TGG GGT TTC ACA TTA TTT GGC TGG GGC CTC CCT	1075
Glu Lys Lys Tyr Leu Trp Gly Phe Thr Leu Phe Gly Trp Gly Leu Pro	
315 320 325	
GCC GTG TTT GTC GCT GTG TGG GTG ACC GTG AGG GCT ACA CTG GCC AAC	1123
Ala Val Phe Val Ala Val Trp Val Thr Val Arg Ala Thr Leu Ala Asn	
330 335 340	
ACT GAG TGC TGG GAC CTG AGT TCG GGG AAT AAG AAA TGG ATC ATA CAG	1171
Thr Glu Cys Trp Asp Leu Ser Ser Gly Asn Lys Lys Trp Ile Ile Gln	
345 350 355	

- 53 -

GTG CCC ATC CTG GCA GCT ATT GTG GTG AAC TTT ATT CTT TTT ATC AAT	1219
Val Pro Ile Leu Ala Ala Ile Val Val Asn Phe Ile Leu Phe Ile Asn	
360 365 370	
ATA ATC AGA GTC CTG GCT ACT AAA CTC CGG GAG ACC AAT GCA GGG AGA	1267
Ile Ile Arg Val Leu Ala Thr Lys Leu Arg Glu Thr Asn Ala Gly Arg	
375 380 385 390	
TGT GAC ACG AGG CAA CAG TAT AGA AAG CTG CTG AAG TCC ACG CTA GTC	1315
Cys Asp Thr Arg Gln Gln Tyr Arg Lys Leu Leu Lys Ser Thr Leu Val	
395 400 405	
CTC ATG CCG CTA TTT GGG GTG CAC TAC ATC GTC TTC ATG GCC ACG CCG	1363
Leu Met Pro Leu Phe Gly Val His Tyr Ile Val Phe Met Ala Thr Pro	
410 415 420	
TAC ACA GAA GTA TCA GGG ATT CTT TGG CAA GTC CAA ATG CAC TAT GAA	1411
Tyr Thr Glu Val Ser Gly Ile Leu Trp Gln Val Gln Met His Tyr Glu	
425 430 435	
ATG CTC TTC AAT TCA TTC CAG GGA TTT TTC GTT GCC ATT ATA TAC TGT	1459
Met Leu Phe Asn Ser Phe Gln Gly Phe Phe Val Ala Ile Ile Tyr Cys	
440 445 450	
TTC TGC AAT GGA GAG GTA CAA GCA GAG ATC AAG AAG TCA TGG AGC CGA	1507
Phe Cys Asn Gly Glu Val Gln Ala Glu Ile Lys Lys Ser Trp Ser Arg	
455 460 465 470	
TGG ACC CTG GCC TTG GAC TTC AAG CGG AAG GCC CGG AGT GGC AGC AGT	1555
Trp Thr Leu Ala Leu Asp Phe Lys Arg Lys Ala Arg Ser Gly Ser Ser	
475 480 485	
ACC TAC AGC TAT GGC CCC ATG GTG TCA CAT ACA AGT GTC ACC AAT GTG	1603
Thr Tyr Ser Tyr Gly Pro Met Val Ser His Thr Ser Val Thr Asn Val	
490 495 500	
GGA CCT CGA GGG GGC TGG CCT TGT CCC TCA GCC CTC GAC TAGCTCCTGG	1652
Gly Pro Arg Gly Gly Trp Pro Cys Pro Ser Ala Leu Asp	
505 510 515	
GGCTGGAGCC AGTGCCAATG GCCATCACCA GTTGCCTGGC TATGTGAAGC ATGGTTCCAT	1712
TTCTGAGAAC TCATTGCCTT CATCTGGCCC AGAGCCTGGC ACCAAAGATG ACGGGTATCT	1772
CAATGGCTCT GGACTTTATG AGCCAATGGT TGGGGAACAG CCCCCTCCAC TCCTGGAGGA	1832
GGAGAGAGAG ACAGTCATGT GACCCATATC	1862

- 54 -

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 2:

## (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1863  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

## (xi) SEQUENCE DESCRIPTION: SEQUENCE ID NO: 2:

```

TGGGCACAGC CACCCTGTTG GTAGTCCAGG GGCCAGCCCA CTGAGCTGGC ATATCAGCTG      60
GTGGCCCCGT TGGACTCGGC CCTAGGGAAC GGCGGCG ATG GGA GCG CCC CGG ATC      115
                               Met Gly Ala Pro Arg Ile
                               1           5

TCG CAC AGC CTT GCC TTG CTC CTC TGC TGC TCC GTG CTC AGC TCC GTC      163
Ser His Ser Leu Ala Leu Leu Leu Cys Cys Ser Val Leu Ser Ser Val
          10           15           20

TAC GCA CTG GTG GAT GCC GAT GAT GTC ATA ACG AAG GAG GAG CAG ATC      211
Tyr Ala Leu Val Asp Ala Asp Asp Val Ile Thr Lys Glu Glu Gln Ile
          25           30           35

ATT CTT CTG CGC AAT GCC CAG GCC CAG TGT GAG CAG CGC CTG AAA GAG      259
Ile Leu Leu Arg Asn Ala Gln Ala Gln Cys Glu Gln Arg Leu Lys Glu
          40           45           50

GTC CTC AGG GTC CCT GAA CTT GCT GAA TCT GCC AAA GAC TGG ATG TCA      307
Val Leu Arg Val Pro Glu Leu Ala Glu Ser Ala Lys Asp Trp Met Ser
          55           60           65           70

AGG TCT GCA AAG ACA AAG AAG GAG AAA CCT GCA GAA AAG CTT TAT CCC      355
Arg Ser Ala Lys Thr Lys Lys Glu Lys Pro Ala Glu Lys Leu Tyr Pro
          75           80           85

CAG GCA GAG GAG TCC AGG GAA GTT TCT GAC AGG AGC CGG CTG CAG GAT      403
Gln Ala Glu Glu Ser Arg Glu Val Ser Asp Arg Ser Arg Leu Gln Asp
          90           95           100

GGC TTC TGC CTA CCT GAG TGG GAC AAC ATT GTG TGC TGG CCT GCT GGA      451
Gly Phe Cys Leu Pro Glu Trp Asp Asn Ile Val Cys Trp Pro Ala Gly
          105           110           115

GTG CCC GGC AAG GTG GTG GCC GTG CCC TGC CCC GAC TAC TTC TAC GAC      499
Val Pro Gly Lys Val Val Ala Val Pro Cys Pro Asp Tyr Phe Tyr Asp
          120           125           130

```

- 55 -

TTC AAC CAC AAA GGC CGA GCC TAT CGG CGC TGT GAC AGC AAT GGC AGC	547
Phe Asn His Lys Gly Arg Ala Tyr Arg Arg Cys Asp Ser Asn Gly Ser	
135 140 145 150	
TGG GAG CTG GTG CCT GGG AAC AAC CGG ACA TGG GCG AAT TAC AGC GAA	595
Trp Glu Leu Val Pro Gly Asn Asn Arg Thr Trp Ala Asn Tyr Ser Glu	
155 160 165	
TGT GTC AAG TTT CTG ACC AAC GAG ACC CGG GAA CGG GAA GTC TTT GAT	643
Cys Val Lys Phe Leu Thr Asn Glu Thr Arg Glu Arg Glu Val Phe Asp	
170 175 180	
CGC CTC GGA ATG ATC TAC ACT GTG GGC TAC TCC ATC TCT CTG GGC TCC	691
Arg Leu Gly Met Ile Tyr Thr Val Gly Tyr Ser Ile Ser Leu Gly Ser	
185 190 195	
CTC ACT GTG GCT GTG CTG ATT CTG GGT TAC TTT AGG AGG TTA CAT TGC	739
Leu Thr Val Ala Val Leu Ile Leu Gly Tyr Phe Arg Arg Leu His Cys	
200 205 210	
ACC CGA AAC TAC ATT CAC ATG CAT CTC TTC GTG TCC TTT ATG CTC CGG	787
Thr Arg Asn Tyr Ile His Met His Leu Phe Val Ser Phe Met Leu Arg	
215 220 225 230	
GCT GTA AGC ATC TTC ATC AAG GAT GCT GTG CTC TAC TCG GGG GTT TCC	835
Ala Val Ser Ile Phe Ile Lys Asp Ala Val Leu Tyr Ser Gly Val Ser	
235 240 245	
ACA GAT GAA ATC GAG CGC ATC ACC GAG GAG GAG CTG AGG GCC TTC ACA	883
Thr Asp Glu Ile Glu Arg Ile Thr Glu Glu Glu Leu Arg Ala Phe Thr	
250 255 260	
GAG CCT CCC CCT GCT GAC AAG GCG GGT TTT GTG GGC TGC AGA GTG GCG	931
Glu Pro Pro Ala Asp Lys Ala Gly Phe Val Gly Cys Arg Val Ala	
265 270 275	
GTA ACC GTC TTC CTT TAC TTC CTG ACC ACC AAC TAC TAC TGG ATC CTG	979
Val Thr Val Phe Leu Tyr Phe Leu Thr Thr Asn Tyr Tyr Trp Ile Leu	
280 285 290	
GTG GAA GGC CTC TAC CTT CAC AGC CTC ATC TTC ATG GCT TTT TTC TCT	1027
Val Glu Gly Leu Tyr Leu His Ser Leu Ile Phe Met Ala Phe Phe Ser	
295 300 305 310	
GAG AAA AAG TAT CTC TGG GGT TTC ACA TTA TTT GGC TGG GGC CTC CCT	1075
Glu Lys Lys Tyr Leu Trp Gly Phe Thr Leu Phe Gly Trp Gly Leu Pro	
315 320 325	
GCC GTG TTT GTC GCT GTG TGG GTG ACC GTG AGG GCT ACA CTG GCC AAC	1123
Ala Val Phe Val Ala Val Trp Val Thr Val Arg Ala Thr Leu Ala Asn	
330 335 340	

- 56 -

ACT GAG TGC TGG GAC CTG AGT TCG GGG AAT AAG AAA TGG ATC ATA CAG	1171
Thr Glu Cys Trp Asp Leu Ser Ser Gly Asn Lys Lys Trp Ile Ile Gln	
345 350 355	
GTG CCC ATC CTG GCA GCT ATT GTG GTG AAC TTT ATT CTT TTT ATC AAT	1219
Val Pro Ile Leu Ala Ala Ile Val Val Asn Phe Ile Leu Phe Ile Asn	
360 365 370	
ATA ATC AGA GTC CTG GCT ACT AAA CTC CGG GAG ACC AAT GCA GGG AGA	1267
Ile Ile Arg Val Leu Ala Thr Lys Leu Arg Glu Thr Asn Ala Gly Arg	
375 380 385 390	
TGT GAC ACG AGG CAA CAG TAT AGA AAG CTG CTG AAG TCC ACG CTA GTC	1315
Cys Asp Thr Arg Gln Gln Tyr Arg Lys Leu Leu Lys Ser Thr Leu Val	
395 400 405	
CTC ATG CCG CTA TTT GGG GTG CAC TAC ATC GTC TTC ATG GCC ACG CCG	1363
Leu Met Pro Leu Phe Gly Val His Tyr Ile Val Phe Met Ala Thr Pro	
410 415 420	
TAC ACA GAA GTA TCA GGG ATT CTT TGG CAA GTC CAA ATG CAC TAT GAA	1411
Tyr Thr Glu Val Ser Gly Ile Leu Trp Gln Val Gln Met His Tyr Glu	
425 430 435	
ATG CTC TTC AAT TCA TTC CAG GGA TTT TTC GTT GCC ATT ATA TAC TGT	1459
Met Leu Phe Asn Ser Phe Gln Gly Phe Phe Val Ala Ile Ile Tyr Cys	
440 445 450	
TTC TGC AAT GGA GAG GTA CAA GCA GAG ATC AAG AAG TCA TGG AGC CGA	1507
Phe Cys Asn Gly Glu Val Gln Ala Glu Ile Lys Lys Ser Trp Ser Arg	
455 460 465 470	
TGG ACC CTG GCC TTG GAC TTC AAG CGG AAG GCC CGG AGT GGC AGC AGT	1555
Trp Thr Leu Ala Leu Asp Phe Lys Arg Lys Ala Arg Ser Gly Ser Ser	
475 480 485	
ACC TAC AGC TAT GGC CCC ATG GTG TCA CAT ACA AGT GTC ACC AAT GTG	1603
Thr Tyr Ser Tyr Gly Pro Met Val Ser His Thr Ser Val Thr Asn Val	
490 495 500	
GGA CCT CGA GGG GGG CTG GCC TTG TCC CTC AGC CCT CGA CTA GCT CCT	1651
Gly Pro Arg Gly Gly Leu Ala Leu Ser Leu Ser Pro Arg Leu Ala Pro	
505 510 515	
GGG GCT GGA GCC AGT GCC AAT GGC CAT CAC CAG TTG CCT GGC TAT GTG	1699
Gly Ala Gly Ala Ser Ala Asn Gly His His Gln Leu Pro Gly Tyr Val	
520 525 530	
AAG CAT GGT TCC ATT TCT GAG AAC TCA TTG CCT TCA TCT GGC CCA GAG	1747
Lys His Gly Ser Il Ser Glu Asn Ser Leu Pro Ser Ser Gly Pro Glu	
535 540 545 550	

- 57 -

[illegible]

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 3:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 2051  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: double  
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQUENCE ID NO: 3:

GGCGGGGGCC	CGCGCGGCGA	GCTCGGAGGC	CGGCGGCGGC	TGCCCGAGG	GACGCGGCC	60
TAGGCGGTGG	CG ATG GGG GCC GCC CGG ATC GCA CCC AGC CTG GCG CTC	108				
	Met Gly Ala Ala Arg Ile Ala Pro Ser Leu Ala Leu					
	1 5 10					
CTA CTC TGC TGC CCA GTG CTC AGC TCC GCA TAT GCG CTG GTG GAT GCG	156					
Leu Leu Cys Cys Pro Val Leu Ser Ser Ala Tyr Ala Leu Val Asp Ala						
	15 20 25					
GAC GAT GTC TTT ACC AAA GAG GAA CAG ATT TTC CTG CTG CAC CGT GCC	204					
Asp Asp Val Phe Thr Lys Glu Gln Ile Phe Leu Leu His Arg Ala						
	30 35 40					
CAG GCG CAA TGT GAC AAG CTG CTC AAG GAA GTT CTG CAC ACA GCA GCC	252					
Gln Ala Gln Cys Asp Lys Leu Leu Lys Glu Val Leu His Thr Ala Ala						
	45 50 55 60					
AAC ATA ATG GAG TCA GAC AAG GGC TGG ACA CCA GCA TCT ACG TCA GGG	300					
Asn Ile Met Glu Ser Asp Lys Gly Trp Thr Pro Ala Ser Thr Ser Gly						
	65 70 75					
AAG CCC AGG AAA GAG AAG GCA TCG GGA AAG TTC TAC CCT GAG TCT AAA	348					
Lys Pro Arg Lys Glu Lys Ala Ser Gly Lys Phe Tyr Pro Glu Ser Lys						
	80 85 90					
GAG AAC AAG GAC GTG CCC ACC GGC AGC AGG CGC AGA GGG CGT CCC TGT	396					
Glu Asn Lys Asp Val Pro Thr Gly Ser Arg Arg Arg Gly Arg Pro Cys						
	95 100 105					

- 58 -

CTG CCC GAG TGG GAC AAC ATC GTT TGC TGG CCA TTA GGG GCA CCA GGT	444
Leu Pro Glu Trp Asp Asn Ile Val Cys Trp Pro Leu Gly Ala Pro Gly	
110 115 120	
GAA GTG GTG GCA GTA CCT TGT CCC GAT TAC ATT TAT GAC TTC AAT CAC	492
Glu Val Val Ala Val Pro Cys Pro Asp Tyr Ile Tyr Asp Phe Asn His	
125 130 135 140	
AAA GGC CAT GCC TAC AGA CGC TGT GAC CGC AAT GGC AGC TGG GAG GTG	540
Lys Gly His Ala Tyr Arg Arg Cys Asp Arg Asn Gly Ser Trp Glu Val	
145 150 155	
GTT CCA GGG CAC AAC CGG ACG TGG GCC AAC TAC AGC GAG TGC CTC AAG	588
Val Pro Gly His Asn Arg Thr Trp Ala Asn Tyr Ser Glu Cys Leu Lys	
160 165 170	
TTC ATG ACC AAT GAG ACG CGG GAA CGG GAG GTA TTT GAC CGC CTA GGC	636
Phe Met Thr Asn Glu Thr Arg Glu Arg Glu Val Phe Asp Arg Leu Gly	
175 180 185	
ATG ATC TAC ACC GTG GGA TAC TCC ATG TCT CTC GCC TCC CTC ACG GTG	684
Met Ile Tyr Thr Val Gly Tyr Ser Met Ser Leu Ala Ser Leu Thr Val	
190 195 200	
GCT GTG CTC ATC CTG GCC TAT TTT AGG CGG CTG CAC TGC ACG CGC AAC	732
Ala Val Leu Ile Leu Ala Tyr Phe Arg Arg Leu His Cys Thr Arg Asn	
205 210 215 220	
TAC ATC CAC ATG CAC ATG TTC CTG TCG TTT ATG CTG CGC GCC GCG AGC	780
Tyr Ile His Met His Met Phe Leu Ser Phe Met Leu Arg Ala Ala Ser	
225 230 235	
ATC TTC GTG AAG GAC GCT GTG CTC TAC TCT GGC TTC ACG CTG GAT GAG	828
Ile Phe Val Lys Asp Ala Val Leu Tyr Ser Gly Phe Thr Leu Asp Glu	
240 245 250	
GCC GAG CGC CTC ACA GAG GAA GAG TTG CAC ATC ATC GCG CAG GTG CCA	876
Ala Glu Arg Leu Thr Glu Glu Glu Leu His Ile Ile Ala Gln Val Pro	
255 260 265	
CCT CCG CCG GCC GCT GCC GCC GTA GGC TAC GCT GGC TGC CGC GTG GCG	924
Pro Pro Pro Ala Ala Ala Val Gly Tyr Ala Gly Cys Arg Val Ala	
270 275 280	
GTG ACC TTC TTC CTC TAC TTC CTG GCT ACC AAC TAC TAC TGG ATT CTG	972
Val Thr Phe Phe Leu Tyr Phe Leu Ala Thr Asn Tyr Tyr Trp Ile Leu	
285 290 295 300	
GTG GAG GGG CTG TAC TTG CAC AGC CTC ATC TTC ATG GCC TTT TTC TCA	1020
Val Glu Gly Leu Tyr Leu His Ser Leu Ile Phe Met Ala Phe Phe Ser	
305 310 315	

- 59 -

GAG AAG AAG TAC CTG TGG GGC TTC ACC ATC TTT GGC TGG GGT CTA CCG	1068
Glu Lys Lys Tyr Leu Trp Gly Phe Thr Ile Phe Gly Trp Gly Leu Pro	
320 325 330	
GCT GTC TTC GTG GCT GTG TGG GTC GGT GTC AGA GCA ACC TTG GCC AAC	1116
Ala Val Phe Val Ala Val Trp Val Gly Val Arg Ala Thr Leu Ala Asn	
335 340 345	
ACT GGG TGC TGG GAT CTG AGC TCC GGG CAC AAG AAG TGG ATC ATC CAG	1164
Thr Gly Cys Trp Asp Leu Ser Ser Gly His Lys Lys Trp Ile Ile Gln	
350 355 360	
GTG CCC ATC CTG GCA TCT GTT GTG CTC AAC TTC ATC CTT TTT ATC AAC	1212
Val Pro Ile Leu Ala Ser Val Val Leu Asn Phe Ile Leu Phe Ile Asn	
365 370 375 380	
ATC ATC CGG GTG CTT GCC ACT AAG CTT CGG GAG ACC AAT GCG GGC CGG	1260
Ile Ile Arg Val Leu Ala Thr Lys Leu Arg Glu Thr Asn Ala Gly Arg	
385 390 395	
TGT GAC ACC AGG CAG CAG TAC CGG AAG CTG CTC AGG TCC ACG TTG GTG	1308
Cys Asp Thr Arg Gln Gln Tyr Arg Lys Leu Leu Arg Ser Thr Leu Val	
400 405 410	
CTC GTG CCG CTC TTT GGT GTC CAC TAC ACC GTC TTC ATG GCC TTG CCG	1356
Leu Val Pro Leu Phe Gly Val His Tyr Thr Val Phe Met Ala Leu Pro	
415 420 425	
TAC ACC GAG GTC TCA GGG ACA TTG TGG CAG ATC CAG ATG CAT TAT GAG	1404
Tyr Thr Glu Val Ser Gly Thr Leu Trp Gln Ile Gln Met His Tyr Glu	
430 435 440 445	
ATG CTC TTC AAC TCC TTC CAG GGA TTT TTT GTT GCC ATC ATA TAC TGT	1452
Met Leu Phe Asn Ser Phe Gln Gly Phe Phe Val Ala Ile Ile Tyr Cys	
450 455 460	
TTC TGC AAT GGT GAG GTG CAG GCA GAG ATT AGG AAG TCA TGG AGC CGC	1500
Phe Cys Asn Gly Glu Val Gln Ala Glu Ile Arg Lys Ser Trp Ser Arg	
465 470 475	
TGG ACA CTG GCG TTG GAC TTC AAG CGC AAA GCA CGA AGT GGG AGT AGC	1548
Trp Thr Leu Ala Leu Asp Phe Lys Arg Lys Ala Arg Ser Gly Ser Ser	
480 485 490	
AGC TAC AGC TAT GGC CCA ATG GTG TCT CAC ACG AGT GTG ACC AAT GTG	1596
Ser Tyr Ser Tyr Gly Pro Met Val Ser His Thr Ser Val Thr Asn Val	
495 500 505	
GGC CCC CGT GCA GGA CTC AGC CTC CCC CTC AGC CCC CGC CTG CCT CCT	1644
Gly Pro Arg Ala Gly Leu Ser Leu Pro Leu Ser Pro Arg Leu Pro Pro	
510 515 520 525	

- 60 -

GCC ACT ACC AAT GGC CAC TCC CAG CTG CCT GGC CAT GCC AAG CCA GGG 1692  
 Ala Thr Thr Asn Gly His Ser Gln Leu Pro Gly His Ala Lys Pro Gly  
                     530                    535                    540

GCT CCA GCC ACT GAG ACT GAA ACC CTA CCA GTC ACT ATG GCG GTT CCC 1740  
 Ala Pro Ala Thr Glu Thr Glu Thr Leu Pro Val Thr Met Ala Val Pro  
                     545                    550                    555

AAG GAC GAT GGA TTC CTT AAC GGC TCC TGC TCA GGC CTG GAT GAG GAG 1788  
 Lys Asp Asp Gly Phe Leu Asn Gly Ser Cys Ser Gly Leu Asp Glu Glu  
                     560                    565                    570

GCC TCC GGG TCT GCG CGG CCG CCT CCA TTG TTG CAG GAA GGA TGG GAA 1836  
 Ala Ser Gly Ser Ala Arg Pro Pro Pro Leu Leu Gln Glu Gly Trp Glu  
                     575                    580                    585

ACA GTC ATG TGA CTGGGCA CTAGGGGGCT AGACTGCTGG CCTGGGCACA 1885  
 Thr Val Met  
                     590

TGGACAGATG GACCAAGAAG CCAGTGT TTG GCTGGTTGTC TATTCGGGAT CTGGACCAGG 1945  
 AAGATAACAA AAGGAAAATG GAAGTGGACG AAGCAGAGAA GAAGGAAGAG GTTTTGCAGG 2005  
 AATTAAATAT GTTTCCTCAG TTGGATGATG AGGACACAAG GAAGGC 2051

What is claimed is:

- 61 -

Claims

- 1           1.     Isolated DNA comprising a DNA sequence  
2     encoding a cell receptor of a vertebrate animal, said  
3     receptor having an amino acid sequence with at least 30%  
4     identity to the amino acid sequence shown in FIG. 3.
- 1           2.     The isolated DNA of claim 1, wherein said  
2     DNA sequence encodes substantially all of the amino acid  
3     sequence shown in FIG. 1 (SEQ. ID NO. 1).
- 1           3.     The isolated DNA of claim 1, wherein said  
2     DNA sequence encodes substantially all of the amino acid  
3     sequence shown in FIG. 3 (SEQ. ID NO. 3).
- 1           4.     The isolated DNA of claim 1, said isolated  
2     DNA being (8A6), deposited with the ATCC and designated  
3     ATCC Accession No. 68570.
- 1           5.     The isolated DNA of claim 1, wherein said  
2     DNA sequence encodes substantially all of the amino acid  
3     sequence shown in Fig. 6 (SEQ. ID. NO. 4).
- 1           6.     The isolated DNA of claim 1, wherein said  
2     DNA sequence hybridizes to the DNA sequence shown in Fig.  
3     1 (SEQ. ID NO. 1).
- 1           7.     The isolated DNA of claim 1, wherein said  
2     DNA sequence hybridizes to the DNA sequence shown in Fig.  
3     3 (SEQ. ID NO. 3).
- 1           8.     The isolated DNA of claim 1, wherein said  
2     DNA sequence hybridizes to the DNA sequence shown in Fig.  
3     6 (SEQ. ID NO. 4).

- 62 -

1           9.    A purified preparation of a vector, said  
2 vector comprising a DNA sequence encoding a parathyroid  
3 hormone receptor.

1           10.   A cell containing the isolated DNA of claim  
2 1.

1           11.   The cell of claim 10, wherein said cell is  
2 capable of expressing said cell receptor from said  
3 isolated DNA.

1           12.   An essentially homogenous population of  
2 cells, each of which comprises the isolated DNA of claim  
3 1.

1           13.   Isolated DNA comprising a DNA sequence  
2 encoding a polypeptide capable of binding parathyroid  
3 hormone or parathyroid-hormone-related protein.

1           14.   A method for producing a polypeptide, said  
2 method comprising:

3                providing a cell comprising isolated DNA  
4 encoding a parathyroid hormone receptor or a fragment  
5 thereof; and

6                culturing said cell under conditions  
7 permitting expression of a polypeptide from said DNA.

1           15.   A single-stranded DNA comprising a portion  
2 of a parathyroid hormone receptor gene, said portion  
3 being at least 18 nucleotides long.

1           16.   The single-stranded DNA of claim 15, wherein  
2 said portion is less than all of said parathyroid hormone  
3 receptor gene.

- 63 -

1           17. The single-stranded DNA of claim 15, wherein  
2 said DNA is detectably labeled.

1           18. A single-stranded DNA comprising a portion  
2 of a parathyroid hormone receptor cDNA, said portion  
3 being at least 18 nucleotides long.

1           19. The single-stranded DNA of claim 18, wherein  
2 said DNA is antisense.

1           20. Parathyroid hormone receptor produced by  
2 expression of a recombinant DNA molecule encoding a  
3 parathyroid hormone receptor.

1           21. An essentially purified preparation of the  
2 parathyroid hormone receptor of claim 20.

1           22. An essentially purified preparation of the  
2 parathyroid receptor produced by the expression of the  
3 DNA of claim 5.

1           23. A polypeptide comprising at least six amino  
2 acids and less than the complete amino acid sequence of a  
3 parathyroid hormone receptor, said polypeptide capable of  
4 binding parathyroid hormone or parathyroid hormone-  
5 related protein.

1           24. The polypeptide of claim 23, wherein said  
2 parathyroid hormone receptor is a human parathyroid  
3 receptor.

1           25. The polypeptide of claim 23, wherein said  
2 fragment comprises

3           (a) TNETREREVFDR LGMIYTVG,

4           (b) YLYSGFTLDEAERLTEEEL,

- 64 -

- 5 (c) VTFFLYFLATNYYWILVEG,  
6 (d) Y-RATLANTGCWDLSSGHKKWIIQVP,  
7 (e) PYTEYSGTLWQIQMHYEM,  
8 (f) DDVFTKEEQIFLLHRAQA,  
9 (g) FFRLHCTRNY,  
10 (h) EKKYLWGFTL,  
11 (i) VLATKLRETNAGRCDTRQQYRKLLK, or  
12 (j) a fragment of (a) - (i) which is capable of  
13 binding parathyroid hormone or parathyroid hormone-  
14 related protein.

1 26. A therapeutic composition comprising, in a  
2 pharmaceutically-acceptable carrier, (a) a parathyroid  
3 hormone receptor or (b) a polypeptide comprising a  
4 fragment of said receptor.

1 27. An antibody capable of forming an immune  
2 complex with a parathyroid hormone receptor.

1 28. A therapeutic composition comprising the  
2 antibody of claim 27 and a pharmaceutically-acceptable  
3 carrier.

1 29. A method of reducing the level of calcium in  
2 the blood of a mammal, which method comprises  
3 administering the therapeutic composition of claim 26 to  
4 said mammal in a dosage effective to inhibit activation  
5 by parathyroid hormone or parathyroid hormone-related  
6 protein of a parathyroid hormone receptor of said mammal.

1 30. A method of reducing the level of calcium in  
2 the blood of a mammal, which method comprises  
3 administering the therapeutic composition of claim 28 to  
4 said mammal in a dosage effective to inhibit activation

- 65 -

5 by parathyroid hormone or parathyroid hormone-related  
6 protein of a parathyroid hormone receptor of said mammal.

1 31. A method for identifying a compound capable  
2 of competing with a parathyroid hormone for binding to a  
3 parathyroid hormone receptor, said method comprising:  
4 (a) contacting the polypeptide of claim 23 with  
5 a parathyroid hormone, (i) in the presence or (ii) in the  
6 absence of a candidate compound; and  
7 (b) comparing (i) the level of binding of said  
8 polypeptide to said parathyroid hormone in the presence  
9 of said candidate compound, with (ii) the level of  
10 binding of said polypeptide to said parathyroid hormone  
11 in the absence of said candidate compound; a lower level  
12 of binding in the presence of said candidate compound  
13 than in its absence indicating that said candidate  
14 compound is capable of competing with said parathyroid  
15 hormone for binding to said receptor.

1 32. A method for identifying a compound capable  
2 of competing with a parathyroid hormone-related protein  
3 for binding to a parathyroid hormone receptor, said  
4 method comprising:  
5 (a) contacting the polypeptide of claim 23 with  
6 a parathyroid hormone-related protein, (i) in the  
7 presence or (ii) in the absence of a candidate compound;  
8 and  
9 (b) comparing (i) the level of binding of said  
10 polypeptide to said parathyroid hormone-related protein  
11 in the presence of said candidate compound, with (ii) the  
12 level of binding of said polypeptide to said parathyroid  
13 hormone-related protein in the absence of said candidate  
14 compound; a lower level of binding in the presence of  
15 said candidate compound than in its absence indicating  
16 that said candidate compound is capable of competing with

- 66 -

17 said parathyroid hormone-related protein for binding to  
18 said receptor.

1 33. A method for identifying a compound capable  
2 of competing with a parathyroid hormone for binding to a  
3 parathyroid hormone receptor, said method comprising:

4 (a) combining a parathyroid hormone with the  
5 cell of claim 11, (i) in the presence or (ii) in the  
6 absence of a candidate compound; and

7 (b) comparing (i) the level of binding of said  
8 receptor to said parathyroid hormone in the presence of  
9 said candidate compound, with (ii) the level of binding  
10 of said receptor to said parathyroid hormone in the  
11 absence of said candidate compound; a lower level of  
12 binding in the presence of said candidate compound than  
13 in its absence indicating that said candidate compound is  
14 capable of competing with said parathyroid hormone for  
15 binding to said receptor.

1 34. A compound capable of inhibiting the binding  
2 of parathyroid hormone or parathyroid hormone-related  
3 protein to a parathyroid receptor on the surface of a  
4 cell.

1 35. A therapeutic composition comprising the  
2 compound of claim 34 and a pharmaceutically-acceptable  
3 carrier.

1 36. A method for identifying a DNA sequence  
2 homologous to a parathyroid hormone receptor-encoding DNA  
3 sequence, said method comprising:

4 providing a genomic or cDNA library;  
5 contacting said library with the single-  
6 stranded DNA of claim 18, under conditions permitting

- 67 -

7 hybridization between said single-stranded DNA and a  
8 homologous DNA sequence in said library; and  
9 identifying a clone from said library which  
10 hybridizes to said single-stranded DNA, said  
11 hybridization being indicative of the presence in said  
12 clone of a DNA sequence homologous to a parathyroid  
13 hormone receptor-encoding DNA sequence.

1 37. A transgenic non-human vertebrate animal  
2 bearing a transgene comprising a DNA sequence encoding  
3 parathyroid hormone receptor or a fragment thereof.

1 38. A diagnostic method comprising:  
2 (a) obtaining a first blood sample from an  
3 animal; (b) administering the composition of claim  
4 35 to said animal;  
5 (c) obtaining a second blood sample from said  
6 animal subsequent to said administration of said  
7 composition; and  
8 (d) comparing the calcium level in said first  
9 blood sample with that in said second blood sample, a  
10 lower calcium level in said second blood sample being  
11 diagnostic for a parathyroid hormone-related condition.

12 39. The isolated DNA of claim 1, wherein said  
13 DNA sequence encodes a parathyroid hormone receptor.

1  
2 40. The parathyroid hormone receptor of claim 20  
3 for use in therapy or diagnosis.

4 41. The polypeptide of claim 23 for use in  
5 therapy or diagnosis.

6 42. The antibody of claim 27 for use in therapy  
7 or diagnosis.

- 68 -

8           43. The therapeutic composition of claim 26 for  
9 use in therapy for the inhibition of activation by  
10 parathyroid hormone or parathyroid hormone-related  
11 protein of a parathyroid hormone receptor of a mammal or  
12 for the reduction of the level of calcium in the blood of  
13 a mammal.

14           44. The therapeutic composition of claim 28 for  
15 use in therapy for the inhibition of activation by  
16 parathyroid hormone or parathyroid hormone-related  
17 protein of a parathyroid hormone receptor of a mammal or  
18 for the reduction of the level of calcium in the blood of  
19 a mammal.

20           45. The parathyroid hormone receptor of claim 20  
21 for use in the manufacture of a medicament for use in  
22 therapy for the inhibition of activation by parathyroid  
23 hormone or parathyroid hormone-related protein of a  
24 parathyroid hormone receptor of a mammal or for the  
25 reduction of the level of calcium in the blood of a  
26 mammal.

27           46. The polypeptide of claim 23 for use in the  
28 manufacture of a medicament for use in therapy for the  
29 inhibition of activation by parathyroid hormone or  
30 parathyroid hormone-related protein of a parathyroid  
31 hormone receptor of a mammal or for the reduction of the  
32 level of calcium in the blood of a mammal.

33           47. The antibody of claim 27 for use in the  
34 manufacture of a medicament for use in therapy for the  
35 inhibition of activation by parathyroid hormone or  
36 parathyroid hormone-related protein of a parathyroid  
37 hormone receptor of a mammal or for the reduction of the  
38 level of calcium in the blood of a mammal.

- 69 -

39           48. A method for identifying a hypercalcemic  
40 condition in a patient which is mediated by parathyroid  
41 hormone or parathyroid hormone-related protein, the  
42 method comprising

43           (a) determining the calcium level of a first  
44 blood sample from the patient,

45           (b) determining the calcium level of a second  
46 blood sample from the patient taken at a time subsequent  
47 after administration of the therapeutic composition of  
48 claim 26, and

49           (c) comparing the calcium levels of the two  
50 blood samples, a lower calcium level in the second blood  
51 sample being indicative of a condition related to  
52 parathyroid hormone or parathyroid hormone-related  
53 protein in the patient.

54           49. A method for identifying a hypercalcemic  
55 condition in a patient which is mediated by parathyroid  
56 hormone or parathyroid hormone-related protein, the  
57 method comprising

58           (a) determining the calcium level of a first  
59 blood sample from the patient,

60           (b) determining the calcium level of a second  
61 blood sample from the patient taken at a subsequent time  
62 after administration of the therapeutic composition of  
63 claim 28, and

64           (c) comparing the calcium levels of the two  
65 blood samples, a lower calcium level in the second blood  
66 sample being indicative of a condition related to  
67 parathyroid hormone or parathyroid hormone-related  
68 protein in the patient.

FIG. 1

TGGGCACAGC CACCCTGTTG GTAGTCCAGG GGCCAGCCCA CTGAGCTGGC ATATCAGCTG																60
GTGGCCCCGT TGGACTCGGC CCTAGGGAAC GGCGGCG ATG GGA GCG CCC CGG ATC																115
Met Gly Ala Pro Arg Ile																
1 5																
TCG	CAC	AGC	CTT	GCC	TTG	CTC	CTC	TGC	TGC	TCC	GTG	CTC	AGC	TCC	GTC	157
Ser	His	Ser	Leu	Ala	Leu	Leu	Leu	Cys	Cys	Ser	Val	Leu	Ser	Ser	Val	
10 15 20																
TAC	GCA	CTG	GTG	GAT	GCC	GAT	GAT	GTC	ATA	ACG	AAG	GAG	GAG	CAG	ATC	211
Tyr	Ala	Leu	Val	Asp	Ala	Asp	Asp	Val	Ile	Thr	Lys	Glu	Glu	Gln	Ile	
25 30 35																
ATT	CTT	CTG	CGC	AAT	GCC	CAG	GCC	CAG	TGT	GAG	CAG	CGC	CTG	AAA	GAG	259
Ile	Leu	Leu	Arg	Asn	Ala	Gln	Ala	Gln	Cys	Glu	Gln	Arg	Leu	Lys	Glu	
40 45 50																
GTC	CTC	AGG	GTC	CCT	GAA	CTT	GCT	GAA	TCT	GCC	AAA	GAC	TGG	ATG	TCA	307
Val	Leu	Arg	Val	Pro	Glu	Leu	Ala	Glu	Ser	Ala	Lys	Asp	Trp	Met	Ser	
55 60 65 70																
AGG	TCT	GCA	AAG	ACA	AAG	AAG	GAG	AAA	CCT	GCA	GAA	AAG	CTT	TAT	CCC	355
Arg	Ser	Ala	Lys	Thr	Lys	Lys	Glu	Lys	Pro	Ala	Glu	Lys	Leu	Tyr	Pro	
75 80 85																
CAG	GCA	GAG	GAG	TCC	AGG	GAA	GTT	TCT	GAC	AGG	AGC	CGG	CTG	CAG	GAT	403
Gln	Ala	Glu	Glu	Ser	Arg	Glu	Val	Ser	Asp	Arg	Ser	Arg	Leu	Gln	Asp	
90 95 100																
EGC	TTC	TGC	CTA	CCT	GAG	TGG	TAC	AAC	ATT	GTG	TGC	TGG	CCT	GCT	GGA	411
Gly	Phe	Cys	Leu	Pro	Glu	Trp	Asp	Asn	Ile	Val	Cys	Trp	Pro	Ala	Gly	
105 110 115																
GTG	CCC	GGC	AAG	GTG	GTG	GCC	GTG	CCC	TGC	CCC	GAC	TAC	TTC	TAC	GAC	499
Val	Pro	Gly	Lys	Val	Val	Ala	Val	Pro	Cys	Pro	Asp	Tyr	Phe	Tyr	Asp	
120 125 130																
TTC	AAC	CAC	AAA	GGC	CGA	GCC	TAT	CGG	CGC	TGT	GAC	AGC	AAT	GGC	AGC	547
Phe	Asn	His	Lys	Gly	Arg	Ala	Tyr	Arg	Arg	Cys	Asp	Ser	Asn	Gly	Ser	
135 140 145 150																
TGG	GAG	CTG	GTG	CCT	GGG	AAC	AAC	CGG	ACA	TGG	GCG	AAT	TAC	AGC	GAA	595
Trp	Glu	Leu	Val	Pro	Gly	Asn	Asn	Arg	Thr	Trp	Ala	Asn	Tyr	Ser	Glu	
155 160 165																
TGT	GTC	AAG	TTT	CTG	ACC	AAC	GAG	ACC	CGG	GAA	CGG	GAA	GTC	TTT	GAT	643
Cys	Val	Lys	Phe	Leu	Thr	Asn	Glu	Thr	Arg	Glu	Arg	Glu	Val	Phe	Asp	
170 175 180																

FIG. 1

CGC	CTC	GGA	ATG	ATC	TAC	ACT	GTG	GGC	TAC	TCC	ATC	TCT	CTG	GGC	TCC	691
Arg	Leu	Gly	Met	Ile	Tyr	Thr	Val	Gly	Tyr	Ser	Ile	Ser	Leu	Gly	Ser	
		185					190					195				
CTC	ACT	GTG	GCT	GTG	CTG	ATT	CTG	GGT	TAC	TTT	AGG	AGG	TTA	CAT	TGC	739
Leu	Thr	Val	Ala	Val	Leu	Ile	Leu	Gly	Tyr	Phe	Arg	Arg	Leu	His	Cys	
	200					205					210					
ACC	CGA	AAC	TAC	ATT	CAC	ATG	CAT	CTC	TTC	GTG	TCC	TTT	ATG	CTC	CGG	787
Thr	Arg	Asn	Tyr	Ile	His	Met	His	Leu	Phe	Val	Ser	Phe	Met	Leu	Arg	
215					220					225					230	
GCT	GTA	AGC	ATC	TTC	ATC	AAG	GAT	GCT	GTG	CTC	TAC	TCG	GGG	GTT	TCC	835
Ala	Val	Ser	Ile	Phe	Ile	Lys	Asp	Ala	Val	Leu	Tyr	Ser	Gly	Val	Ser	
				235					240					245		
ACA	GAT	GAA	ATC	GAG	CGC	ATC	ACC	GAG	GAG	GAG	CTG	AGG	GCC	TTC	ACA	883
Thr	Asp	Glu	Ile	Glu	Arg	Ile	Thr	Glu	Glu	Glu	Leu	Arg	Ala	Phe	Thr	
			250					255					260			
GAG	CCT	CCC	CCT	GCT	GAC	AAG	GCG	GGT	TTT	GTG	GGC	TGC	AGA	GTG	GCG	931
Glu	Pro	Pro	Pro	Ala	Asp	Lys	Ala	Gly	Phe	Val	Gly	Cys	Arg	Val	Ala	
		265					270					275				
GTA	ACC	GTC	TTC	CTT	TAC	TTC	CTG	ACC	ACC	AAC	TAC	TAC	TGG	ATC	CTG	979
Val	Thr	Val	Phe	Leu	Tyr	Phe	Leu	Thr	Thr	Asn	Tyr	Tyr	Trp	Ile	Leu	
	280					285					290					
GTG	GAA	GGC	CTC	TAC	CTT	CAC	AGC	CTC	ATC	TTC	ATG	GCT	TTT	TTC	TCT	1027
Val	Glu	Gly	Leu	Tyr	Leu	His	Ser	Leu	Ile	Phe	Met	Ala	Phe	Phe	Ser	
295					300					305					310	
GAG	AAA	AAG	TAT	CTC	TGG	GGT	TTC	ACA	TTA	TTT	GGC	TGG	GGC	CTC	CCT	1075
Glu	Lys	Lys	Tyr	Leu	Trp	Gly	Phe	Thr	Leu	Phe	Gly	Trp	Gly	Leu	Pro	
				315					320					325		
ACC	GTG	TTT	CTC	GCT	GTG	TGG	ATC	ACC	GTG	AGG	GCT	ACA	CTG	GCC	AAC	1123
Ala	Val	Phe	Val	Ala	Val	Trp	Val	Thr	Val	Arg	Ala	Thr	Leu	Ala	Asn	
			330					335					340			
ACT	GAG	TGC	TGG	GAC	CTG	AGT	TGG	GGG	AAT	AAG	AAA	TGG	ATC	ATA	CAG	1171
Thr	Glu	Cys	Trp	Asp	Leu	Ser	Ser	Gly	Asn	Lys	Lys	Trp	Ile	Ile	Gln	
		345					350					355				
GTG	CCC	ATC	CTG	GCA	GCT	ATT	GTG	CTG	AAC	TTT	ATT	CTT	TTT	ATC	AAT	1219
Val	Pro	Ile	Leu	Ala	Ala	Ile	Val	Val	Asn	Phe	Ile	Leu	Phe	Ile	Asn	
	360					365					370					
ATA	ATC	AGA	GTC	CTG	GCT	ACT	AAA	CTC	GGG	GAG	ACC	AAT	GCA	GGG	AGA	1267
Ile	Ile	Arg	Val	Leu	Ala	Thr	Lys	Leu	Arg	Glu	Thr	Asn	Ala	Gly	Arg	
375					380					385					390	

3/30

FIG. 1

TGT GAC ACG AGG CAA CAG TAT AGA AAG CTG CTG AAG TCC ACG CTA GTC	1315
Cys Asp Thr Arg Gln Gln Tyr Arg Lys Leu Leu Lys Ser Thr Leu Val	
395 400 405	
CTC ATG CCG CTA TTT GGG GTG CAC TAC ATC GTC TTC ATG GCC ACG CCG	1353
Leu Met Pro Leu Phe Gly Val His Tyr Ile Val Phe Met Ala Thr Pro	
410 415 420	
TAC ACA GAA GTA TCA GGG ATT CTT TGG CAA GTC CAA ATG CAC TAT GAA	1411
Tyr Thr Glu Val Ser Gly Ile Leu Trp Gln Val Gln Met His Tyr Glu	
425 430 435	
ATG CTC TTC AAT TCA TTC CAG GGA TTT TTC GTT GCC ATT ATA TAC TGT	1459
Met Leu Phe Asn Ser Phe Gln Gly Phe Phe Val Ala Ile Ile Tyr Cys	
440 445 450	
TTC TGC AAT GGA GAG GTA CAA GCA GAG ATC AAG AAG TCA TGG AGC CGA	1507
Phe Cys Asn Gly Glu Val Gln Ala Glu Ile Lys Lys Ser Trp Ser Arg	
455 460 465 470	
TGG ACC CTG GCC TTG GAC TTC AAG CGG AAG GCC CGG AGT GGC AGC AGT	1555
Trp Thr Leu Ala Leu Asp Phe Lys Arg Lys Ala Arg Ser Gly Ser Ser	
475 480 485	
ACC TAC AGC TAT GGC CCC ATG GTG TCA CAT ACA AGT GTC ACC AAT GTG	1603
Thr Tyr Ser Tyr Gly Pro Met Val Ser His Thr Ser Val Thr Asn Val	
490 495 500	
GGA CCT CGA GGG GGC TGG CCT TGT CCC TCA GCC CTC GAC TAGCTCCTGG	1652
Gly Pro Arg Gly Gly Trp Pro Cys Pro Ser Ala Leu Asp	
505 510 515	
GGCTGGAGCC AGTGCCAATG GCCATCACCA GTTGCCTGGC TATGTGAAGC ATGGTTCCAT	1712
TTCTGAGAAC TCATTGCCTT CATCTGGCCC AGAGCCTGGC ACCAAAGATG ACGGGTATCT	1772
CAATGGCTCT GGACTTTATG AGCCAATGGT TGGGGAACAG CCCCCTCCAC TCCTGGAGGA	1832
GGAGAGAGAG ACAGTCATGT GACCCATATC	1862

FIG. 2

TGGGCACAGC	CACCCTGTTG	GTAGTCCAGG	GGCCAGCCCA	CTGAGCTGGC	ATATCAGCTG	60
GTGGCCCCGT	TGGA	CTCGGC	CCTAGGGAAC	GGCGGCG	ATG GGA GCG CCC CGG ATC	115
					Met Gly Ala Pro Arg Ile	
					1 5	
TCG CAC AGC CTT GCC TTG CTC CTC TGC TGC TCC GTG CTC AGC TCC GTC	163					
Ser His Ser Leu Ala Leu Leu Leu Cys Cys Ser Val Leu Ser Ser Val						
	10 15 20					
TAC GCA CTG GTG GAT GCC GAT GAT GTC ATA ACG AAG GAG GAG CAG ATC	211					
Tyr Ala Leu Val Asp Ala Asp Asp Val Ile Thr Lys Glu Glu Gln Ile						
	25 30 35					
ATT CTT CTG CGC AAT GCC CAG GCC CAG TGT GAG CAG CGC CTG AAA GAG	259					
Ile Leu Leu Arg Asn Ala Gln Ala Gln Cys Glu Gln Arg Leu Lys Glu						
	40 45 50					
GTC CTC AGG GTC CCT GAA CTT GCT GAA TCT GCC AAA GAC TGG ATG TCA	307					
Val Leu Arg Val Pro Glu Leu Ala Glu Ser Ala Lys Asp Trp Met Ser						
	55 60 65 70					
AGG TCT GCA AAG ACA AAG AAG GAG AAA CCT GCA GAA AAG CTT TAT CCC	355					
Arg Ser Ala Lys Thr Lys Lys Glu Lys Pro Ala Glu Lys Leu Tyr Pro						
	75 80 85					
CAG GCA GAG GAG TCC AGG GAA GTT TCT GAC AGG AGC CGG CTG CAG GAT	403					
Gln Ala Glu Glu Ser Arg Glu Val Ser Asp Arg Ser Arg Leu Gln Asp						
	90 95 100					
GGC TTC TGC CTA CCT GAG TGG GAC AAC ATT GTG TGC TGG CCT GCT GGA	451					
Gly Phe Cys Leu Pro Glu Trp Ser Ile Val Cys Trp Pro Ala Gly						
	105 110 115					
GTG CCC GGC AAG GTG GTG GCC GTC CCC TGC CCC GAC TAC TTC TAC GAC	499					
Val Pro Gly Lys Val Val Ala Val Trp Cys Pro Asp Tyr Phe Tyr Asp						
	120 125 130					
TTC AAC CAC AAA GGC CGA GCC TAT CGG CGC TGT GAC AGC AAT GGC AGC	547					
Phe Asn His Lys Gly Arg Ala Tyr Arg Arg Cys Asp Ser Asn Gly Ser						
	135 140 145 150					
TGG GAG CTG GTG CCT GGG AAC AAC CGG ACA TGG GCG AAT TAC AGC GAA	595					
Trp Glu Leu Val Pro Gly Asn Asn Arg Thr Trp Ala Asn Tyr Ser Glu						
	155 160 165					
TGT GTC AAG TTT CTG ACC AAC GAG ACC CGG GAA CGG GAA GTC TTT GAT	643					
Cys Val Lys Phe Leu Thr Asn Glu Thr Arg Glu Arg Glu Val Phe Asp						
	170 175 180					

5/30

FIG. 2

2 of 2

CGC CTC GGA ATG ATC TAC ACT GTG GGC TAC TCC ATC TCT CTG GGC TCC Arg Leu Gly Met Ile Tyr Thr Val Gly Tyr Ser Ile Ser Leu Gly Ser 185 190 195	691
CTC ACT GTG GCT GTG CTG ATT CTG GGT TAC TTT AGG AGG TTA CAT TGC Leu Thr Val Ala Val Leu Ile Leu Gly Tyr Phe Arg Arg Leu His Cys 200 205 210	700
ACC CGA AAC TAC ATT CAC ATG CAT CTC TTC GTG TCC TTT ATG CTC CGG Thr Arg Asn Tyr Ile His Met His Leu Phe Val Ser Phe Met Leu Arg 215 220 225 230	787
GCT GTA AGC ATC TTC ATC AAG GAT GCT GTG CTC TAC TCG GGG GTT TCC Ala Val Ser Ile Phe Ile Lys Asp Ala Val Leu Tyr Ser Gly Val Ser 235 240 245	835
ACA GAT GAA ATC GAG CGC ATC ACC GAG GAG GAG CTG AGG GCC TTC ACA Thr Asp Glu Ile Glu Arg Ile Thr Glu Glu Glu Leu Arg Ala Phe Thr 250 255 260	883
GAG CCT CCC CCT GCT GAC AAG GCG GGT TTT GTG GGC TGC AGA GTG GCG Glu Pro Pro Pro Ala Asp Lys Ala Gly Phe Val Gly Cys Arg Val Ala 265 270 275	931
GTA ACC GTC TTC CTT TAC TTC CTG ACC ACC AAC TAC TAC TGG ATC CTG Val Thr Val Phe Leu Tyr Phe Leu Thr Thr Asn Tyr Tyr Trp Ile Leu 280 285 290	979
GTG GAA GGC CTC TAC CTT CAC AGC CTC ATC TTC ATG GCT TTT TTC TCT Val Glu Gly Leu Tyr Leu His Ser Leu Ile Phe Met Ala Phe Phe Ser 295 300 305 310	1027
GAG AAA AAG TAT CTC TGG GGT TTC ACA TTA TTT GGC TGG GGC CTC CCT Glu Lys Lys Tyr Leu Trp Gly Phe Thr Leu Phe Gly Trp Gly Leu Pro 315 320 325	1075
GCC GTG TTT GTC GCT GTG TGG GTG ACC GTG AGG GCT ACA CTG GCC AAC Ala Val Phe Val Ala Val Trp Val Thr Val Arg Ala Thr Leu Ala Asn 330 335 340	1120
ACT GAG TGC TGG GAC CTG AGT TCG GGG AAT AAG AAA TGG ATC ATA CAG Thr Glu Cys Trp Asp Leu Ser Ser Gly Asn Lys Lys Trp Ile Ile Gln 345 350 355	1171
GTG CCC ATC CTG GCA GCT ATT GTG GTG AAC TTT ATT CTT TTT ATC AAT Val Pro Ile Leu Ala Ala Ile Val Val Asn Phe Ile Leu Phe Ile Asn 360 365 370	1219
ATA ATC AGA GTC CTG GCT ACT AAA CTC CGG GAG ACC AAT GCA GGG AGA Ile Ile Arg Val Leu Ala Thr Lys Leu Arg Glu Thr Asn Ala Gly Arg 375 380 385 390	1267

6/30

FIG. 2

3 of 3

[illegible]

7/30

FIG. 3

1 of 3

GGCGGGGGCC	GCGGCGGCGA	GCTCGGAGGC	CGGCGGCGGC	TGCCCCGAGG	GACGCGGCCC	60										
TAGGCGGTGG	CG	ATG	GGG	GCC	GCC	CGG	ATC	GCA	CCC	AGC	CTG	GCG	CTC	108		
		Met	Gly	Ala	Ala	Arg	Ile	Ala	Pro	Ser	Leu	Ala	Leu			
		1				5					10					
CTA	CTC	TGC	TGC	CCA	GTG	CTC	AGC	TCC	GCA	TAT	GCG	CTG	GTG	GAT	GCG	120
Leu	Leu	Cys	Cys	Pro	Val	Leu	Ser	Ser	Ala	Tyr	Ala	Leu	Val	Asp	Ala	
		15				20					25					
GAC	GAT	GTC	TTT	ACC	AAA	GAG	GAA	CAG	ATT	TTC	CTG	CTG	CAC	CGT	GCC	204
Asp	Asp	Val	Phe	Thr	Lys	Glu	Glu	Gln	Ile	Phe	Leu	Leu	His	Arg	Ala	
	30					35					40					
CAG	GCG	CAA	TGT	GAC	AAG	CTG	CTC	AAG	GAA	GTT	CTG	CAC	ACA	GCA	GCC	228
Gln	Ala	Gln	Cys	Asp	Lys	Leu	Leu	Lys	Glu	Val	Leu	His	Thr	Ala	Ala	
	45				50					55					60	
AAC	ATA	ATG	GAG	TCA	GAC	AAG	GGC	TGG	ACA	CCA	GCA	TCT	ACG	TCA	GGG	300
Asn	Ile	Met	Glu	Ser	Asp	Lys	Gly	Trp	Thr	Pro	Ala	Ser	Thr	Ser	Gly	
				65				70						75		
AAG	CCC	AGG	AAA	GAG	AAG	GCA	TCG	GGA	AAG	TTC	TAC	CCT	GAG	TCT	AAA	348
Lys	Pro	Arg	Lys	Glu	Lys	Ala	Ser	Gly	Lys	Phe	Tyr	Pro	Glu	Ser	Lys	
			80					85					90			
GAG	AAC	AAG	GAC	GTG	CCC	ACC	GGC	AGC	AGG	CGC	AGA	GGG	CGT	CCC	TGT	396
Glu	Asn	Lys	Asp	Val	Pro	Thr	Gly	Ser	Arg	Arg	Arg	Gly	Arg	Pro	Cys	
		95					100					105				
CTG	CCC	GAG	TGG	GAC	AAC	ATC	GTT	TGC	TGG	CCA	TTA	GGG	GCA	CCA	GGT	444
Leu	Pro	Glu	Trp	Asp	Asn	Ile	Val	Cys	Trp	Pro	Leu	Gly	Ala	Pro	Gly	
	110					115					120					
GAA	GTG	GTG	GCA	GTA	CCT	TGT	CCC	GAT	TAC	ATT	TAT	GAC	TTC	AAT	CAC	492
Glu	Val	Val	Ala	Val	Pro	Cys	Pro	Asp	Tyr	Ile	Tyr	Asp	Phe	Asn	His	
	125				130				135						140	
AAA	GGC	CAT	GCC	TAC	AGA	CGC	TGT	GAC	CGC	AAT	GGC	AGC	TGG	GAG	GTG	540
Lys	Gly	His	Ala	Tyr	Arg	Arg	Cys	Asp	Arg	Asn	Gly	Ser	Trp	Glu	Val	
				145				150					155			
GTT	CCA	GGG	CAC	AAC	CGG	ACG	TGG	GCC	AAC	TAC	AGC	GAG	TGC	CTC	AAG	588
Val	Pro	Gly	His	Asn	Arg	Thr	Trp	Ala	Asn	Tyr	Ser	Glu	Cys	Leu	Lys	
			160				165					170				
TTC	ATG	ACC	AAT	GAG	ACG	CGG	GAA	CGG	GAG	GTA	TTT	GAC	CGC	CTA	GGC	636
Phe	Met	Thr	Asn	Glu	Thr	Arg	Glu	Arg	Glu	Val	Phe	Asp	Arg	Leu	Gly	
		175					180					185				
ATG	ATC	TAC	ACC	GTG	GGA	TAC	TCC	ATG	TCT	CTC	GCC	TCC	CTC	ACG	GTG	684
Met	Ile	Tyr	Thr	Val	Gly	Tyr	Ser	Met	Ser	Leu	Ala	Ser	Leu	Thr	Val	
	190					195					200					

8/30

FIG. 3

2 of 3

GCT Ala 205	GTG Val	CTC Leu	ATC Ile	CTG Leu	GCC Ala 210	TAT Tyr	TTT Phe	AGG Arg	CGG Arg	CTG Leu 215	CAC His	TGC Cys	ACG Thr	CGC Arg 220	AAC Asn	732
TAC Tyr	ATC Ile	CAC His	ATG Met	CAC His 225	ATG Met	TTC Phe	CTG Leu	TCG Ser	TTT Phe 230	ATG Met	CTG Leu	CGC Arg	GCC Ala	GCG Ala 235	AGC Ser	780
ATC Ile	TTC Phe	GTG Val	AAG Lys 240	GAC Asp	GCT Ala	GTG Val	CTC Leu	TAC Tyr 245	TCT Ser	GGC Gly	TTC Phe	ACG Thr	CTG Leu 250	GAT Asp	GAG Glu	828
GCC Ala	GAG Glu 255	CGC Arg	CTC Leu	ACA Thr	GAG Glu	GAA Glu	GAG Glu 260	TTG Leu	CAC His	ATC Ile	ATC Ile	GCG Ala 265	CAG Gln	GTG Val	CCA Pro	876
CCT Pro 270	CCG Pro	CCG Pro	GCC Ala	GCT Ala	GCC Ala	GCC Ala 275	GTA Val	GGC Gly	TAC Tyr	GCT Ala	GGC Gly 280	TGC Cys	CGC Arg	GTG Val	GCG Ala	924
GTG Val 285	ACC Thr	TTC Phe	TTC Phe	CTC Leu 290	TAC Tyr	TTC Phe	CTG Leu	GCT Ala	ACC Thr 295	AAC Asn	TAC Tyr	TAC Tyr	TGG Trp	ATT Ile 300	CTG Leu	972
GTG Val	GAG Glu	GGG Gly	CTG Leu 305	TAC Tyr	TTG Leu	CAC His	AGC Ser	CTC Leu 310	ATC Ile	TTC Phe	ATG Met	GCC Ala	TTT Phe 315	TTC Phe	TCA Ser	1020
GAG Glu	AAG Lys	AAG Lys 320	TAC Tyr	CTG Leu	TGG Trp	GGC Gly	TTC Phe 325	ACC Thr	ATC Ile	TTT Phe	GGC Gly	TGG Trp 330	GGT Gly	CTA Leu	CCG Pro	1068
GCT Ala 335	GTC Val	TTC Phe	GTG Val	GCT Ala	GTG Val	TGG Trp 340	GTC Val	GGT Gly	GTC Val	AGA Arg	GCA Ala 345	ACC Thr	TTG Leu	GCC Ala	AAC Asn	1116
ACT Thr 350	GGG Gly	TGC Cys	TGG Trp	GAT Asp	CTG Leu 355	AGC Ser	TCC Ser	GGG Gly	CAC His	AAG Lys 360	AAG Lys	TGG Trp	ATC Ile	ATC Ile	CAG Gln 365	1164
GTG Val	CCC Pro	ATC Ile	CTG Leu	GCA Ala 370	TCT Ser	GTT Val	GTG Val	CTC Leu 375	CAC Asn	TTC Phe	ATC Ile	CTT Leu	TTT Phe	ATC Ile 380	AAC Asn	1212
ATC Ile	ATC Ile	CGG Arg	GTG Val 385	CTT Leu	GCC Ala	ACT Thr	AAG Lys	CTT Leu 390	CGG Arg	GAG Glu	ACC Thr	AAT Asn	GCG Ala 395	GGC Gly	CGG Arg	1260
TGT Cys	GAC Asp	ACC Thr 400	AGG Arg	CAG Gln	CAG Gln	TAC Tyr	CGG Arg 405	AAG Lys	CTG Leu	CTC Leu	AGG Arg	TCC Ser	ACG Thr	TTG Leu	GTG Val	1308

9/30

3 of 3

FIG. 3

CTC	GTG	CCG	CTC	TTT	GGT	GTC	CAC	TAC	ACC	GTC	TTC	ATG	GCC	TTG	CCG	1356
Leu	Val	Pro	Leu	Phe	Gly	Val	His	Tyr	Thr	Val	Phe	Met	Ala	Leu	Pro	
415						420					425					
TAC	ACC	GAG	GTC	TCA	GGG	ACA	TTG	TGG	CAG	ATC	CAG	ATG	CAT	TAT	GAG	1404
Tyr	Thr	Glu	Val	Ser	Gly	Thr	Leu	Trp	Gln	Ile	Gln	Met	His	Tyr	Glu	
430					435					440					445	
ATG	CTC	TTC	AAC	TCC	TTC	CAG	GGA	TTT	TTT	GTT	GCC	ATC	ATA	TAC	TGT	1452
Met	Leu	Phe	Asn	Ser	Phe	Gln	Gly	Phe	Phe	Val	Ala	Ile	Ile	Tyr	Cys	
				450					455						460	
TTC	TGC	AAT	GGT	GAG	GTG	CAG	GCA	GAG	ATT	AGG	AAG	TCA	TGG	AGC	CGC	1500
Phe	Cys	Asn	Gly	Glu	Val	Gln	Ala	Glu	Ile	Arg	Lys	Ser	Trp	Ser	Arg	
			465					470					475			
TGG	ACA	CTG	GCG	TTG	GAC	TTC	AAG	CGC	AAA	GCA	CGA	AGT	GGG	AGT	AGC	1548
Trp	Thr	Leu	Ala	Leu	Asp	Phe	Lys	Arg	Lys	Ala	Arg	Ser	Gly	Ser	Ser	
		480					485					490				
AGC	TAC	AGC	TAT	GGC	CCA	ATG	GTG	TCT	CAC	ACG	AGT	GTG	ACC	AAT	GTG	1596
Ser	Tyr	Ser	Tyr	Gly	Pro	Met	Val	Ser	His	Thr	Ser	Val	Thr	Asn	Val	
	495					500					505					
GGC	CCC	CGT	GCA	GGA	CTC	AGC	CTC	CCC	CTC	AGC	CCC	CGC	CTG	CCT	CCT	1644
Gly	Pro	Arg	Ala	Gly	Leu	Ser	Leu	Pro	Leu	Ser	Pro	Arg	Leu	Pro	Pro	
510					515					520					525	
GCC	ACT	ACC	AAT	GGC	CAC	TCC	CAG	CTG	CCT	GGC	CAT	GCC	AAG	CCA	GGG	1692
Ala	Thr	Thr	Asn	Gly	His	Ser	Gln	Leu	Pro	Gly	His	Ala	Lys	Pro	Gly	
				530					535					540		
GCT	CCA	GCC	ACT	GAG	ACT	GAA	ACC	CTA	CCA	GTC	ACT	ATG	GCG	GTT	CCC	1740
Ala	Pro	Ala	Thr	Glu	Thr	Glu	Thr	Leu	Pro	Val	Thr	Met	Ala	Val	Pro	
			545					550					555			
AAG	GAC	GAT	GGA	TTC	CTT	AAC	GGC	TCC	TGC	TCA	GGC	CTG	GAT	GAG	GAG	1788
Lys	Asp	Asp	Gly	Phe	Leu	Asn	Gly	Ser	Cys	Ser	Gly	Leu	Asp	Glu	Glu	
		560					565					570				
GCC	TCC	GGG	TCT	GCG	CGG	CCG	CCT	CCA	TTG	TTG	CAG	GAA	GGA	TGG	GAA	1836
Ala	Ser	Gly	Ser	Ala	Arg	Pro	Pro	Pro	Leu	Leu	Gln	Glu	Gly	Trp	Glu	
	575					580					585					
ACA	GTC	ATG	TGACTGGGCA	CTAGGGGGGCT	AGACTGCTGG	CCTGGGCACA	1885									
Thr	Val	Met														
590																
TGGACAGATG	GACCAAGAAG	CCAGTGT	TTTG	GCTGGTTGTC	TATTCGGGAT	CTGGACCAGG	1945									
AAGATAACAA	AAGGAAAATG	GAAGTGGACG	AAGCAGAGAA	GAAGGAAGAG	GTTTTGCAGG	2005										
AATTAAATAT	GTTTCCTCAG	TTGGATGATG	AGGACACAAG	GAAGGC		2051										

10/30

Fig. 4

```

1 MGAARIAPSLALLCCPVLSAYALVDADDVFTKEZQIFLLHBAQAQCDK 50
  |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
1 MGAPRISHSLALLCCSVLSSVYALVDADDVITKEZQIILLRNAQAQCEQ 50

51 LLKEVLHTAANIMESDKGHTPASTSGKPRKERASGKFPYPSKENKDVPTG 100
  |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
51 RLKEVLR.VPELAESAQDW..MSRSAKTKKXKPAEKLYPQAEZSREVSDR 97

101 SRRGRPCLPFWDNIWCWPLGAPGEVVAVPCPDYIYDFNHKGHAYRRCDR 150
  ||..|||||:|||||:|||||:|||||:|||||:|||||:|||||:
98 SRLQDGFCLPFDNIWCWPAAGVPGKVAVPCPDYFYDFNHKGGRAYRRCD 147

151 NGSWEVVPGHNRWTANYSECLAFMTNETREREVDRLGHIYTVGYSHSLA 200
  |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
148 NGSWEVVPGHNRWTANYSECVKPLTNETREREVDRLGHIYTVGYSLSLG 197

201 SLTVAVLILAYFRRLHCTRNYYIMHMFSLFHLRAASIFVKDAVLYSGFTL 250
  |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
198 SLTVAVLILGYFRRLHCTRNYYIMHMLFVSLFHLRAVSIFIKDAVLYSGV 247

251 DEAERLTEEELHIIAQVPPPPAAAAGVYAGCRVAVTFFLYFLATNYYWIL 300
  |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
248 DEERITEEELRAFTE...PPPADKAGFVGCRAVTVFLYFLTTNYYWIL 294

301 VEGLYLHSLIFMAFFSEKKYLWGFTIFGWGLFAVFVAVVWGVVRATLANTG 350
  |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
295 VEGLYLHSLIFMAFFSEKKYLWGFTIFGWGLFAVFVAVVWTVRATLANTE 344

351 CNDLSSGHRKRWIIQVPILASVVLNFIILFINIIRVLATKLRETNAGCDTR 400
  |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
345 CNDLSSGHRKRWIIQVPILAAIVVNFIILFINIIRVLATKLRETNAGCDTR 394

401 QQYRKLLRSTLVLPFGVHYTVFMALPYTEVSGTLWQIQMHYENLFSF 450
  |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
395 QQYRKLLRSTLVLPFGVHYIVFMATPYTEVSGTLWQVQMHYENLFSF 444

451 QGFFVAIIYCFNGEVOAEIKKSWSRWTLALDFKKRARSGLSSSYSGPMV 500
  |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
445 QGFFVAIIYCFNGEVOAEIKKSWSRWTLALDFKKRARSGLSSTSYSGPMV 494

501 SHTSVTVNGFRAGLSLPLSPRLPP...ATTNGHSQLPGRHAKPGAPATETZ 547
  |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
495 SHTSVTVNGFRAGLSLPLSPRLAPGAGASANGERQLPGYVKEGSIENSL 544

548 TLZVTMAVPRDDGFLNGSCSGLDEEASGSARPPPLLOEGWETVR. 591
  |||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:
545 PSSGFEPGTXDDGYLNG..SGLYEPHVG.EQPPPLLEEERETVR* 586

```

Gap Weight:	3.000	Average Match:	0.540
Length Weight:	0.100	Average Mismatch:	-0.396
Quality:	712.2	Length:	595
Ratio:	1.215	Gaps:	6
Percent Similarity:	87.113	Percent Identity:	77.835

11/30

Fig. 5

```

R15 MGAARIAPSL ALLLCCPVLS SAYALVDADD VFTKEEQIFL LHRQAQOCDK 50
OkO MGAPRISHSL ALLLCCSVLS SVYALVDADD VITKEEQIIL LRNAQAQCEQ 50
Okh MGAPRISHSL ALLLCCSVLS SVYALVDADD VITKEEQIIL LRNAQAQCEQ 50
----- A -----

R15 LLKEVLHTAA NIMESDKGWT PASTSGKPRK EKASGKFYPE SKENKDVPTG 100
OkO RLKEVLR.VP ELAESAKDW. .MSRSAKTRK EKPAEKLYPO AEESREVSOR 97
Okh RLKEVLR.VP ELAESAKDW. .MSRSAKTRK EKPAEKLYPO AEESREVSOR 97

R15 SRRRGRPCLP EWDNIVCWPL GAPGEVVAVP CPDYIYDFNH KGHAYRRCDR 150
OkO SRLQDGFCLP EWDNIVCWPA GVPKVVAVP CPDYFYDFNH KGRAYRRCDR 147
Okh SRLQDGFCLP EWDNIVCWPA GVPKVVAVP CPDYFYDFNH KGRAYRRCDR 147
----- B -----

R15 NGSWEVVP GH NRTWANYSEC LKFMETNETRE REVFDRLGMI YTVGYSMSLA 200
OkO NGSWEVVP GH NRTWANYSEC VKFLTNETRE REVFDRLGMI YTVGYSISLG 197
Okh NGSWEVVP GH NRTWANYSEC VKFLTNETRE REVFDRLGMI YTVGYSISLG 197
----- C -----

R15 SLTVAVLILA YFRRHLHCTRN YIHMMLFVSF MLRAASIFVK DAVLYSGFTL 250
OkO SLTVAVLILG YFRRHLHCTRN YIHMMLFVSF MLRAVSIFIK DAVLYSGVST 247
Okh SLTVAVLILG YFRRHLHCTRN YIHMMLFVSF MLRAVSIFIK DAVLYSGVST 247
----- D -----

R15 DEAEERLTEEE LHIIAQVPPP PAAAVGYAG CRVAVTFPLY FLATNYXWIL 300
OkO DEAEERITEEE LRAFTE...P PPADKAGFVG CRVAVTFPLY FLATNYXWIL 294
Okh DEAEERITEEE LRAFTE...P PPADKAGFVG CRVAVTFPLY FLATNYXWIL 294
----- E -----

R15 VEGLYLHSLI FMAFFSEKKY LWGFTLFGWG LPAVFVAVWV GVRATLANTG 350
OkO VEGLYLHSLI FMAFFSEKKY LWGFTLFGWG LPAVFVAVWV TVRATLANTE 344
Okh VEGLYLHSLI FMAFFSEKKY LWGFTLFGWG LPAVFVAVWV TVRATLANTE 344
----- F -----

R15 CWDLSSGHKK WIIQVPILAS VVLNFIILFIN IIRVLATKLR ETNAGRCDDR 400
OkO CWDLSSGNKK WIIQVPILAA IVVNFIILFIN IIRVLATKLR ETNAGRCDDR 394
Okh CWDLSSGNKK WIIQVPILAA IVVNFIILFIN IIRVLATKLR ETNAGRCDDR 394
----- G -----

R15 QQYRKLLRST LVLVPLFGVH YTVFMALPYT EVSGTLWQIQ MHEMLFNFSF 450
OkO QQYRKLLXST LVLVPLFGVH YIVFMATPYT EVSGILWQVQ MHEMLFNFSF 444
Okh QQYRKLLKST LVLVPLFGVH YIVFMATPYT EVSGILWQVQ MHEMLFNFSF 444
----- H -----

R15 QGFFVAIIYC FCNGEVOAEI RKSWSRWTLA LDFKRRKARS SSSYSYGPMV 500
OkO QGFFVAIIYC FCNGEVOAEI KKSWSRWTLA LDFKRRKARS SSTYSYGPMV 494
Okh QGFFVAIIYC FCNGEVOAEI KKSWSRWTLA LDFKRRKARS SSTYSYGPMV 494
----- I -----

R15 SHTSVTNVGP RAGLSLPLSP RLFP...ATT NGHSQLPGEA KPGAPATETE 547
OkO SHTSVTNVGP RGGALSLSLSP RLAPGAGASA NGHBQLPGYV KHGSISENSL 544
Okh SHTSVTNVGP RGG..... LD 515

R15 TLPVTMAVPK DDGFLNGSCS GLDEEASGSA RPPPLLQEGW ETVM 591
OkO PSSGPEPGTK DDGYLNG..S GLYEPVVG.E QPPPLLEER ETVM 585

```

12/30

FIG. 6

With 1 enzymes: S<sub>ACI</sub>

February 27, 1992 18:30 ..

GGGATCCCGCGGCCCTAGGCGGTGGCGatgggGaccGCccggatcgcacccggcctggcg  
 2 ----- 61  
 CCCTAGGGCGCCGGGATCCGCCACCGctacccCTggCGggcctagcgtgggcccggaccgc  
 b M G T A R I A P G L A -  
 ctctgctctgctgccccgtgctcagctccggctacggcgtggatgcagatgacgtc  
 62 ----- 121  
 gaggacgagacgacggggcacgagtcgaggcgcatgcgcgaccacctacgtctactgcag  
 b L L L C C P V L S S A Y A L V D A D D V -  
 atgactaaagaggaacagatcttccctgctgcacccgtgctcaggcccagtgcgaaaaacgg  
 122 ----- 181  
 tactgattttctccctgctctagaaggacgacgtgggacgagtcgggggtcacgctttctgccc  
 b M T K E E Q I F L L H R A Q A Q C E K R -  
 ctcaaaggaggtccctgcagaggccagccagcataatggaatcagacaagggatggacatct  
 182 ----- 241  
 gaggttccctccaggacgtctccgggtcgggtcgtattaccttagtctgttccctacctgtaga  
 b L K E V L Q R P A S I M E S D K G W T S -  
 gggtccacatcaggggaagcccaggaaagataaaggcatctgggaagctctacccctgagtct  
 242 ----- 301  
 cgcagggtgtagtcccttcgggtccctttctattccgtagacccttcgagatgggactcaga  
 b A S T S G K P R K D K A S G K L Y P E S -  
 gaggaggacaaggaggcaccactggcagcaggtaccgagggcgccctgtctgcccggaa  
 302 ----- 361  
 ctccctccctgttccctccgtgggtgaccgtcgttccctggctcccgggggacagacggcctt  
 b E E D K E A P T G S I R G R P C L P E -  
 tgggaccacatccctgtgctggccgctggggggcaccacgtgaggtggtggctgtgccctgt  
 362 ----- 421  
 accctgggtgtaggacacgaccggcgacccccgtgggtccactccaccaccgacacgggaca  
 b W D H I L C W P L G A P G E V V A V P C -  
 ccggactacatttatgacttcaatcaciaaggccctgcctaccgacgctgtgaccgcaat  
 422 ----- 481  
 ggccctgatgtaaatactgaagttagtgtttccggtagcgatggctgcgacactggcggtta  
 b P D Y I Y D F N H K G A A Y R R C D R N -  
 ggcaagctgggagctcgtgcctggggcacaacaggacctggggccaactacagcgagtgtgtc  
 482 ----- 541  
 ccgtcgaccctcgaccacggacccctgttctccctgcacccgggttgatgtcgctcacacag

13/90

U G S W E L V P G H N E T W A N Z F B C V -  
542 aaattttcttccac atgagactcgtglaacgggaggtgtttgaccgcttgggcatgatttac  
-----+----- 601  
tttaagagtggttactctgagcacttgccctccacaaactggcggaccgactactaaatg

b K F L T N E T R E R E V F D R L G M I Y -  
602 accgtgggctactccgtgtccctggcgtccctcaccgtagctgtgctcatcctggcctac  
-----+----- 661  
tggcacccgatgaggcacagggaaccgcaggagtggtggcatcgacacgagtaggaccggatg

b T V G Y S V S L A S L T V A V L I L A Y -  
662 tttaggcggctgcactgcacgcgcaactacatccacatgcacctgttctgtccttcatg  
-----+----- 721  
aaatccgcccacgtgacgtgcgcgttgatgtaggtgtacgtggacaaggacaggaagtac

b F R R L H C T R N Y I H M H L F L S F M -  
722 ctgcgcgccgtgagcatcttctgcaaggacgctgtgctctactctggcgccacgcttgat  
-----+----- 781  
gacgcgcgggaactcgtagaagcagttctctggcacacgagatgagaccggtgcgaacta

b L R A V S I F V K D A V L Y S G A T L D -  
782 gaggctgagcgcctcaccgaggaggagctgcgcgccatcgcccaggcgccccgcgcgcct  
-----+----- 841  
ctccgactcgcgagtggtctctctcgacgcgcggttagcgggtccgcggggggcgcgga

b E A E R L T E E E L R A I A Q A P P P P -  
842 gccaccgcccgtgccggtacgcgggtgcagggtggctgtgacctttctcttacttc  
-----+----- 901  
cggcggcgccgacggccgatgcgcgccgacgtcccaaccgacactggaagaaggaaatgaag

b A T A A A G Y A G C R V A V T F F L Y F -  
902 ctggccaccaactactactggattctgggtggaggggtgtacctgcacagcctcatcttc  
-----+----- 961  
gaccggtggttgatgatgacctaaagaccacctcccccacatggacgtctcggagtagaag

b L A T N Y Y W E L V E S L Y L H S L I F -  
962 atggccttcttctcagagaagaagtacctgtggggcttcacagtcttctgggtggggtctg  
-----+----- 1021  
taccggaagaagaagtctcttcttcatggacacccccgaagtgtcagaagccgacccccagac

b M A F F S E K K Y L N S F T V F G W G L -  
1022 cccgctgtcttctgggtgtgtgggtcagctgtcagagctaccctggccaacaccgggtgc  
-----+----- 1081  
gggcgacagaagcaccgacacacccagtccagctctcgatgggaaccggtgtggccccag

b P A V F V A V W V S V R A T L A N T G C -

S  
A  
C  
-

14/30

1032 tggtgacttgagctccgggaacaaaaagtcggtatcctccaggtgcccctccctggcctccatt  
----- 1141  
accctgaactcgagggcccttgctctccacctagtaggtccacgggtaggaccggaggttaa

b W D L S E S N K K W I I Q V P I L A S I -

1142 gtgctcaacttcacccctcttcacatatacctccgggtgctcgccaccaagcagcgggag  
----- 1201  
cacgagttgaagtaggagaagtagttatagcagggccacgagcgggtgggttcgctcgccctc

b V L N F I L F I N I V R V L A T K Q R E -

1202 accaacgcggggccgggtgtgacacacggcagcagctaccggaagctgctcaaaccacgctg  
----- 1261  
cgggttgccggccggccacactgtgtgcccgtcgtccatggcccttcgacgagtttaggtgcgac

b T N A G R C D T R C C Y R X L L K S T L -

1262 gtgctcatgcccctctttggcgtccactacattgctcttcattggccacaccatacacccgag  
----- 1321  
cacgagtacgggggagaaaccgcaggtgatgtaacagaagtaccgggtgtggtatgtggctc

b V L M P L F G V H Y I V F M A T P Y T E -

1322 gtctcagggacgctctggcaagtcctgagatccactatgagatgctcttcaactccttccag  
----- 1381  
cagagtcctctgcgagaccgttcagggtctacgtcctactctacgagaagttgaggaaggtc

b V S G T L W Q V Q M H F E M L F N S F Q -

1382 ggattttttgtcgcaatcatatactgtctctccaatggcgaggtacaagctgagatcaag  
----- 1441  
cctaaaaaacagcgttagtatatgacaaaagacgttaccggtcccatgttcgactctagttc

b G F F V A I I Y C F C N S E V Q A E I K -

1442 aaatcttgagcggctggacactggcactggactccagccgaaaggcacgcagcgggagc  
----- 1501  
tttaagaacctcggcgacctgtgacctgaccttaacttcgcttccgtgggtcgccctcg

b K S W S R W T L A L I T R K A R S G S -

1502 agcagctatagctacggcccccctgggtgtcccacaaagtgtgaccaatgtcggcccccg  
----- 1561  
tcgtcgatatcgatcccggggtaccacaggggtgtgtccactggttacagccgggggca

b S S Y S Y G P M V S H T E V T N V G P R -

1562 gtgggactcggcctgcccctcagccccccctcctgcccactgccaccaccaacggccac  
----- 1621  
caccctgagccggacggggagtcggggggcggtatccgggtgacgggtgggtgggtgcccgtg

b V G L G L P L S P R L L P T A T T N G H -

1622 cctcagctgcttggccatgccaaagccagggaccccagccctggagaccctcgagaccaca  
----- 1681  
ggagtcgacggacccgtacgggtcgggtccctgggtcgggacctctgggagctctgggtgt

b P Q L P G H A K P G T P A L E T L E T T -

15/30

1682 ----- 1741  
 ccacctggccatgggtgctcccaaggacgatgggtccctcaacgggtctt: ttgggcctg  
 ggtggacgggtaccgacggggttcttggctacccaaaggagtggccgaggacgagtccggac

b P P A M A A P K D D G F L N G S C S G L -

1742 ----- 1801  
 gacgaggaggcctctgggcctgagcggccacctgacctgctacaggaagagtgggagaca  
 ctgctcctccggagacccggactcgccgggtggacgggacgagtgtcttctcaccctctgt

b D E E A S G P E R P P A L L Q E E W E T -

1802 ----- 1861  
 gtcattgtgaccaggcgctgggggctggacctgctgacatagtggatggacagatggacca  
 cagtacactgggtccgagacccccgacctggacgactgtatcacctacctgtctacctggt

b V M

1862 ----- 1921  
 aaagatgggtggttgaatgatttccactcagggcctggggccaagaggaaaaaacaggg  
 tttctaccaccaaacttactaaagggtgagtcccgaccccggttctctcttttttctccc

b

1922 ----- 1981  
 gaaaaaagaaaaaaaaaagaaaaaaggaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa  
 cttttttctttttttttttcttttttccctttttttttttttttttttttttttttttt

b

1982 ----- 2011  
 aaaaaaaaaaaaaaaaaaaaaaaaaaaaaa  
 ttttttttttttttttttttttttttttttt

b

Enzymes that do cut:

SacI

16/30




Fig. 7






Fig.3

FIG. 9




19/30

FIG. 10




20/30

Fig. 11



21/30

FIG. 12








FIG. 13

FIG. 14



24/30

FIG. 15



25/30

FIG. 16




Fig. 17








Fig. 18



28/30

Fig. 19







Fig. 20



# RAT BONE PTH/PTHrP RECEPTOR



## AMINO ACID SEQUENCE OF 7 PUTATIVE TRANS-MEMBRANE REGIONS



## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US92/02821

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(5) : Please See Extra Sheet.

US CL : 435/69.1, 240.2, 320.1; 536/27, 28, 29; 530/350, 387, 397, 399.

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : APS AND COMMERCIAL DATABASES (DIALOG) 435/69.1, 240.2, 320.1; 536/27, 28, 29

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

DIALOG AND ONLINE SEQUENCE SEARCH

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
<u>X</u> Y	TWENTY-SEVENTH ANNUAL MEETING OF THE AMERICAN SOCIETY FOR CELL BIOLOGY, VOLUME 105, NO. 4, PT. 2, ISSUED OCTOBER 1987, R. A. LUBEN ET AL., "MOLECULAR CLONING OF A PARATHYROID HORMONE RECEPTOR-RELATED MEMBRANE PROTEIN FROM MOUSE BONE CELLS", ENTIRE DOCUMENT.	1-19, 39 20-38, 40-49
Y	THE JOURNAL OF BIOLOGICAL CHEMISTRY, VOL 265, NO. 1, ISSUED 05 JANUARY 1990, ABOU-SAMRA ET AL., "CHARACTERIZATION OF FULLY ACTIVE BIOTINYLATED PARATHYROID HORMONE ANALOGS", PAGES 58-62, ENTIRE DOCUMENT.	1-49 -
Y	BIOCHEMISTRY, VOLUME 29, NO. 30, ISSUED 31 JULY 1990, JUPPNER ET AL., "PREPARATION AND CHARACTERIZATION (N-(4-AZIDO-2-NITROPHENYL)ALA, TYR-36)-PATHYROID HORMONE RELATED PEPTIDE (1-36) AMIDE: A HIGH-AFFINITY, PARTIAL AGONIST HAVING HIGH CROSS-LINKING EFFICIENCY WITH ITS RECEPTOR ON ROS 17/2.8 CELLS", PAGES 6941-6946, ENTIRE DOCUMENT.	1-49



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be part of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means		
"P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search 01 JULY 1992	Date of mailing of the international search report 31 JUL 1992
Name and mailing address of the ISA/ Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No.	Authorized officer GIAN WANG Telephone No. (703) 308-3993

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US92/02821

## A. CLASSIFICATION OF SUBJECT MATTER:

IPC (5):

C12P 21/06; C12N 5/00, 15/00; C07H 15/12, 17/00; C07K 3/00; A61K 35/14, 37/24, 37/36.

## BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING